Compositions and methods for improving sample identification in indexed nucleic acid libraries
By degrading unincorporated adaptors and using modified double-stranded target polynucleotide fragments in library sample preparation, combined with exonuclease treatment, the problem of sequencing results confusion caused by index jump is solved, and the accurate identification of library sources is achieved .
Patent Information
- Application Number
- CN201880042176.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2017-04-23
- Filing Date
- 2018-04-23
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2039-03-28
AI Technical Summary
In the prior art, due to index jumping during polynucleotide sequencing, the sequencing results are confusing, making it difficult to accurately identify the source of the library.
Index skip is reduced by degrading unincorporated adaptors during library sample preparation, using modified double-stranded target polynucleotide fragments and adaptor oligonucleotides, combined with exonuclease treatment.
Effectively reduce index jumps, improve the accuracy of sequencing results, and ensure the correct identification of library sources.
Smart Images

Figure CN111094584B_ABST
Abstract
Description
[0001] Related Applications
[0002] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 488,830, filed on April 23, 2017, which is hereby incorporated by reference in its entirety.
[0003] field
[0004] The present disclosure relates particularly to sequencing polynucleotides from multiple indexed libraries; more particularly, to increasing the likelihood that sequencing correctly identifies the library from which the polynucleotide originated.
[0005] background
[0006] Improvements in sequencing methodology have allowed the sequencing of pooled or multiplexed polynucleotides from different libraries in a single sequencing protocol. Library-specific sequences ("index tags") can be added to the polynucleotides of each library so that the origin of each sequenced polynucleotide can be correctly identified. Index tag sequences can be added to the polynucleotides of a library by, for example, ligating adapters containing the index tag sequences to the ends of the polynucleotides.
[0007] The adapter may include sequences other than the index tag sequence, such as a universal extension primer sequence and a universal sequencing primer sequence. The universal extension primer sequence may be hybridized in particular with a first oligonucleotide coupled to a solid surface. The first oligonucleotide may have a free 3' end, and a polymerase may use the hybridized library polynucleotide as a template to add nucleotides from the free 3' end to extend the sequence, causing the reverse strand of the library polynucleotide to be coupled to a solid surface. Additional copies of the forward strand and the reverse strand may be coupled to a solid surface by cluster amplification. An example of cluster amplification is bridge amplification, in which the 3' end of the previously amplified polynucleotide bound to the solid surface is hybridized with a second oligonucleotide bound to the solid surface. The second oligonucleotide may have a free 3' end, and a polymerase may use the coupled reverse strand polynucleotide as a template to add nucleotides from the free 3' end to extend the sequence, causing the forward strand of the library polynucleotide to be coupled to a solid surface via a second oligonucleotide. The process may be repeated to produce clusters of forward strands and reverse strands coupled to a solid surface. Prior to sequencing, the forward strand or reverse strand may be removed, for example, by cleavage.
[0008] The sequencing primer can be hybridized with a portion of the polynucleotide chain coupled to the solid support. For example, the sequencing primer can be hybridized with a universal sequencing primer sequence (if present). Sequencing can be performed by adding nucleotides to the sequencing primer and detecting the identity of the added nucleotides using the coupled polynucleotide as a template in multiple rounds. The hybridization of the sequencing primer can occur at a position on the coupled polynucleotide chain to allow sequence identification of the index tag sequence and the target sequence of the polynucleotide coupled to the solid surface, or a separate sequencing primer can be used to sequence the index tag sequence and the target sequence separately. Therefore, the target sequence can be indexed to a specific library source based on the index tag sequence associated with the target sequence.
[0009] Although each polynucleic acid to be sequenced contains a library-specific index tag sequence, errors may occur in identifying the library source of the polynucleic acid being sequenced due to a phenomenon known as index hopping. When an index tag sequence from one library is inadvertently added to a polynucleic acid from another library, index hopping occurs. Index hopping may occur during library preparation or during cluster amplification of polynucleotides on a flow cell or other suitable solid support for sequencing. Index hopping may confuse the results of sequencing, such as causing improper designation of the library source of the polynucleotide being sequenced or discarding sequencing results.
[0010] Brief Description
[0011] One or more aspects of the present disclosure solve at least one potential mechanism associated with index jumping by degrading polynucleotides, including target polynucleotides and unincorporated adapters, that do not form adapter-target-adapter polynucleotide sequences during library sample preparation. Without intending to be bound by theory, it is believed that when an unincorporated adapter comprising an index tag sequence for one library hybridizes with a portion of an adapter from another library and the unincorporated adapter is used as a primer during cluster amplification, index jumping may occur. Therefore, a target sequence from one library can be tagged with an index tag from an adapter of another library. During subsequent multiple rounds of cluster amplification, additional copies of the target that was incorrectly tagged may be amplified before sequencing. Such index jumping may confuse the results of subsequent sequencing. By degrading adapters that are not incorporated during library sample preparation, unincorporated adapters from other libraries will not be able to be used as primers during cluster amplification, and therefore, index jumping can be reduced.
[0012] In some aspects described herein, a method includes providing a first more than one double-stranded target polynucleotide fragment. Each of the double-stranded target polynucleotide fragments has a first end and a second end. The method also includes providing a first adapter oligonucleotide comprising a first chain having a 5' end and a 3' end and a second chain having a 5' end and a 3' end. The first adapter oligonucleotide comprises (i) a double-stranded region, the double-stranded region comprising the 5' end of the first chain and the 3' end of the second chain, and (ii) a single-stranded region, in which the first chain and the second chain are single-stranded. The single-stranded region comprises the 3' end of the first chain and the 5' end of the second chain. The first adapter oligonucleotide comprises a first library-specific sequence. The 3' end of the first chain is modified to prevent digestion by an enzyme having 3' exonuclease activity, and the 5' end of the second chain is modified to prevent digestion by an enzyme having 5' exonuclease activity. The method also includes incubating the first adapter oligonucleotide and the first more than one double-stranded target polynucleotide fragment under conditions suitable for connecting the 5' end of the first strand of the first adapter and the 3' end of the second strand of the first adapter to the first end and the second end of the double-stranded target polynucleotide fragment to produce a first library of polynucleotides comprising a first adapter-target-first adapter sequence. The method also includes contacting the polynucleotides of the first library with an exonuclease, which will be understood as one or more exonucleases. The exonuclease includes a 3' single-stranded exonuclease activity and a 5' single-stranded exonuclease activity to selectively degrade the first adapter oligonucleotide that is not connected to the double-stranded target polynucleotide fragment.
[0013] In some aspects described herein, an oligonucleotide adapter for connection to a target polynucleotide prior to sequencing comprises a first oligonucleotide chain having a 5' end and a 3' end; and a second oligonucleotide chain having a 5' end and a 3' end. The region at the 5' end of the first chain comprises nucleotides complementary to the nucleotides in the region at the 3' end of the second chain, such that the complementary region is double-stranded. The region at the 3' end of the first chain and the region at the 5' end of the second chain are sufficiently non-complementary to be single-stranded. At least one of the first chain and the second chain comprises a library-specific index tag sequence. The 3' end of the first chain is modified to prevent digestion by an enzyme having 3' exonuclease activity, and the 5' end of the second chain is modified to prevent digestion by an enzyme having 5' exonuclease activity.
[0014] In some aspects described herein, a kit includes an adaptor and an exonuclease as described in the previous paragraph. In some aspects described herein, a composition includes an adaptor and an exonuclease as described in the previous paragraph.
[0015] In some aspects described herein, a composition comprises more than one polynucleotide comprising a first adapter-target-second adapter sequence. The target sequence is double-stranded. The region of the first adapter near the target is double-stranded. The region of the second adapter near the target is double-stranded. The region of the first adapter distal to the target includes two single strands, each having one end. The region of the second adapter distal to the target includes two single strands, each having one end. At least one of the two single strands of the first adapter or the second adapter comprises a library-specific index tag sequence. Each end of the two single strands of the first adapter and the second adapter is modified to prevent digestion by exonucleases.
[0016] The composition of the previous paragraph may optionally include an adaptor comprising a first oligonucleotide chain having a 5' end and a 3' end and a second oligonucleotide chain having a 5' end and a 3' end. The region at the 5' end of the first chain includes nucleotides complementary to the nucleotides in the region at the 3' end of the second chain, so that the complementary region is double-stranded. The region at the 3' end of the first chain and the region at the 5' end of the second chain are non-complementary enough to become single-stranded. At least one of the first chain and the second chain includes a library-specific index tag sequence. The 3' end of the first chain is modified to prevent digestion by an enzyme having 3' exonuclease activity, and the 5' end of the second chain is modified to prevent digestion by an enzyme having 5' exonuclease activity.
[0017] The composition of either of the first two paragraphs may further comprise an exonuclease.
[0018] The methods, compositions and kits described herein can be used to reduce index jumping, for example, by degrading unincorporated adapters during library sample preparation. By degrading unincorporated adapters, unincorporated adapters will not be available to potentially serve as accidental (inadvertent) extension primers for cluster amplification. In addition, it will be appreciated that degradation of incomplete products, such as target polynucleotides that are not connected to adapters or are only connected to one adapter, will generally be beneficial in reducing the binding of polynucleic acids that cannot be used as effective templates for sequencing to solid supports.
[0019] Additional features and advantages of the subject matter of the present disclosure will be set forth in the detailed description that follows, and in part will be apparent to those skilled in the art from that description, or will be recognized by practicing the subject matter of the present disclosure as described herein, including the following detailed description, claims, and accompanying drawings.
[0020] It will be understood that the foregoing general description and the following detailed description both illustrate embodiments of the subject matter of the present disclosure and are intended to provide an overview or framework for understanding the nature and characteristics of the subject matter of the present disclosure as claimed therein. The accompanying drawings are included to provide a further understanding of the subject matter of the present disclosure and are incorporated into and constitute a part of this specification. The accompanying drawings illustrate multiple embodiments of the subject matter of the present disclosure and are used together with the description to explain the principles and operation of the subject matter of the present disclosure. Additionally, the drawings and descriptions are meant to be illustrative only and are not intended to limit the scope of the claims in any way. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] The following detailed description of specific embodiments of the present disclosure is best understood when read in conjunction with the following drawing figures.
[0023] Figure 1 is a schematic diagram of an embodiment of an adaptor according to aspects of the disclosure presented herein.
[0024] Figure 2 is a method according to aspects of the disclosure presented herein having an adapter-target-adapter sequence (which may include substantially Figure 1 Schematic diagram of an embodiment of a template polynucleotide having an adaptor (shown in ).
[0025] Figure 3 is a schematic diagram illustrating the results of incubating adaptor-target ligation reaction products and reagents with an exonuclease.
[0026] Figure 4 is a diagram illustrating the use of a template polynucleotide (which may be Figure 2 Schematic diagram of an embodiment of a process for cluster amplification of an embodiment of a template polynucleotide (depicted in FIG. 1 ).
[0027] Figure 5 is a schematic diagram illustrating one embodiment of how exonuclease treatment may reduce index hopping according to various embodiments described herein.
[0028] Fig. 6A and 6B The nature of the index jumping phenomenon is illustrated. Fig. 6A It shows how reads from a given sample are incorrectly demultiplexed and mixed with different samples after demultiplexing. Figure 6B We demonstrate index jumping in a dual-index system, where the index jumping leads to unexpected combinations of index label sequences.
[0029] Fig. 7A and 7BA general method for measuring the index jump rate in a given system is illustrated. Fig. 7A An exemplary layout of a dual adaptor plate is shown, where each individual well of a 96-well plate contains a unique pair of index tag sequences. Figure 7B Shown is the experimental setup designed to measure the index jump rate, where only unique dual-index tag combinations are used.
[0030] Fig. 8A and 8B The effect of unligated adaptors on index hopping rate is shown. Fig. 8A A 6-fold increase in the index jump associated with 50% incorporation of free adaptor is shown. Figure 8B A roughly linear effect of free forked adaptors on index jump rate is shown over the range tested.
[0031] Fig. 9 Shown is the effect of combined exonuclease and 3' blocking treatment of protected adapters according to the present invention on index jumping rate with and without free adapter incorporation in an Illumina TruSeq PCR-free library preparation workflow.
[0032] The schematic diagrams are not necessarily to scale. The same numbers used in the drawings refer to similar components, steps, etc. However, it will be understood that the use of a number to refer to a component in a given figure is not intended to limit the use of the same number to label that component in another figure. In addition, the use of different numbers to refer to multiple components is not intended to indicate that the differently numbered components cannot be the same or similar to the other numbered components.
[0033] Detailed Description
[0034] Reference will now be made in greater detail to various embodiments of the subject matter of the present disclosure, some of which are illustrated in the accompanying drawings.
[0035] definition
[0036] Unless otherwise indicated, all scientific and technical terms used herein have the meanings commonly used in the art. The definitions provided herein are to facilitate understanding of certain terms frequently used herein and are not meant to limit the scope of the present disclosure.
[0037] As used herein, the singular forms "a", "an", and "the" include plural referents unless the context clearly indicates otherwise. Thus, for example, reference to an "exonuclease" includes instances of having two or more "exonucleases" unless the context clearly indicates otherwise.
[0038] As used in this specification and the appended claims, the term "or" is generally used in its sense including "and / or" unless the context clearly dictates otherwise. The term "and / or" means one or all of the listed elements or any combination of two or more of the listed elements. The use of "and / or" in some contexts does not imply that the use of "or" in other contexts may not mean "and / or".
[0039] As used herein, “have,” “has,” “having,” “include,” “includes,” “including,” “comprise,” “comprises,” “comprising,” and the like are used in their open, inclusive sense, and generally mean “include, but not limited to,” “includes, but not limited to,” or “including, but not limited to.”
[0040] "Optional" or "optionally" means that the subsequently described event, circumstance or component may or may not occur, and that the description includes instances where the event, circumstance or component occurs and instances where it does not.
[0041] The words "preferred" and "preferably" refer to embodiments of the present disclosure that may provide certain benefits under certain circumstances. However, other embodiments may also be preferred under the same or other circumstances. In addition, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the present invention.
[0042] Also herein, numerical ranges recited by endpoints include all numbers contained in that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.). Where a range of values is "greater than," "less than," etc. a particular value, the value is included in the range.
[0043] Unless otherwise expressly stated, it is not intended that any method described herein be construed as requiring that its steps be performed in a specific order. Therefore, in the event that a method claim does not actually recite the order in which its steps are to be followed or does not otherwise specifically state in the claims or specification that the steps are to be limited to a specific order, no specific order is intended to be inferred. Any recited single or multiple features or aspects in any one claim may be combined or arranged with any other recited features or aspects in any other one or more claims.
[0044] Although the transitional phrase "comprising" may be used to disclose various features, elements, or steps of a particular embodiment, it will be understood that alternative embodiments are implied, including those that may be described using the transitional phrase "consisting" or "consisting essentially of." Thus, for example, implicit alternative embodiments of a polynucleotide comprising an adaptor-target-adaptor sequence include embodiments in which the polynucleotide consists of an adaptor-target-adaptor sequence and embodiments in which the polynucleotide consists essentially of an adaptor-target-adaptor sequence.
[0045] As used herein, "providing" in the context of a compound, composition, or article means preparing the compound, composition, or article, purchasing the compound, composition, or article, or otherwise obtaining the compound, composition, or article.
[0046] As used herein, "amplify," "amplifying," or "amplification reaction," and their derivatives, generally refer to any action or process by which at least a portion of a polynucleotide (e.g., a template polynucleotide) is replicated or copied into at least one additional polynucleotide. The additional polynucleotide optionally includes a sequence that is substantially identical or substantially complementary to at least a portion of the template polynucleotide. The template polynucleotide may be single-stranded or double-stranded, and the additional polynucleotide may be independently single-stranded or double-stranded. Amplification optionally includes linear or exponential replication of the polynucleotide. In some embodiments, such amplification may be performed using isothermal conditions; in other embodiments, such amplification may include thermal cycling. In some embodiments, amplification is a multiplex amplification, which includes simultaneously amplifying more than one target sequence in a single amplification reaction. In some embodiments, "amplification" includes amplification based on at least a portion of a separate DNA nucleic acid and at least a portion of an RNA nucleic acid, or a combination thereof. The amplification reaction may include any amplification process known to those of ordinary skill in the art. In some embodiments, the amplification reaction includes a polymerase chain reaction (PCR).
[0047] As used herein, "amplification conditions" and their derivatives generally refer to conditions suitable for amplifying one or more polynucleotide sequences. Such amplification can be linear or exponential. In some embodiments, amplification conditions may include isothermal conditions, or may alternatively include thermal cycling conditions, or a combination of isothermal and thermal cycling conditions. In some embodiments, conditions suitable for amplifying one or more polynucleotide sequences include polymerase chain reaction (PCR) conditions. Generally, amplification conditions refer to a reaction mixture sufficient to amplify polynucleotides such as one or more target sequences, or to amplify amplified target sequences connected to one or more adapters, such as amplified target sequences connected to adapters. Generally, amplification conditions include catalysts for amplification or for polynucleotide synthesis, such as polymerases; primers having a certain degree of complementarity with the nucleic acid to be amplified; and nucleotides, such as deoxyribonucleotide triphosphates (dNTPs), to promote extension of primers after hybridization with nucleic acids. Amplification conditions may require hybridization or annealing of primers to nucleic acids, extension of primers, and denaturation steps, in which the extended primers are separated from the polynucleotide sequences undergoing amplification. Typically, but not necessarily, amplification conditions may include thermal cycling; in some embodiments, amplification conditions include more than one cycle in which the steps of annealing, extension, and separation are repeated. Typically, amplification conditions include cations such as Mg++ or Mn++ and may also include a variety of ionic strength aids.
[0048] As used herein, the term "polymerase chain reaction" ("PCR") refers to the method of K.B. Mullis U.S. Pat. Nos. 4,683,195 and 4,683,202, which describe a method for increasing the concentration of a segment of a polynucleotide of interest in a mixture of genomic DNA without cloning or purification. This method for amplifying a polynucleotide of interest consists of introducing a large excess of two oligonucleotide primers into a DNA mixture containing the desired polynucleotide of interest, followed by a series of thermal cycles in the presence of a DNA polymerase. The two primers are complementary to the strands of the double-stranded polynucleotide of interest corresponding to them. The mixture is first denatured at a higher temperature, and then the primers are annealed to the complementary sequences within the polynucleotide of the molecule of interest. After annealing, the primers are extended with a polymerase to form a new pair of complementary chains. The steps of denaturation, primer annealing, and polymerase extension can be repeated many times (referred to as thermal cycling) to obtain a high concentration of amplified segments of the desired polynucleotide of interest. The length of the amplified segment (amplicon) of the desired polynucleotide of interest is determined by the relative position of the primers relative to each other, and therefore the length is a controllable parameter. Due to the repetition of this process, the method is referred to as "polymerase chain reaction" (hereinafter referred to as "PCR"). Because the amplified segments of the desired polynucleotide of interest become the main nucleic acid sequences (in terms of concentration) in the mixture, they are referred to as "PCR amplified". When modifying the method discussed above, more than one different primer pair can be used, and in some cases, one or more primer pairs are used for each polynucleotide of interest, thereby forming a multiplex PCR reaction to PCR amplify the polynucleotide.
[0049] As defined herein, "multiplex amplification" refers to the selective and non-random amplification of two or more target sequences in a sample using at least one target-specific primer. In some embodiments, multiple amplification is performed so that some or all of the target sequences are amplified in a single reaction vessel. The "plexy" or "plex" of a given multiple amplification generally refers to the number of different target-specific sequences amplified during the single multiple amplification. In some embodiments, the multiplicity can be about 12-, 24-, 48-, 96-, 192-, 384-, 768-, 1536-, 3072-, 6144- or higher. It is also possible to detect the amplified target sequence by several different methods (e.g., gel electrophoresis followed by density determination (densitometry), quantitatively measured with a bioanalyzer or quantitative PCR, hybridized with labeled probes; incorporation of biotinylated primers followed by avidin-enzyme conjugate detection; 32P-labeled deoxynucleotide triphosphates are incorporated into the amplified target sequence).
[0050] As used herein, the term "primer" and its derivatives generally refer to any polynucleotide that can hybridize with a target sequence of interest. Generally, primers act as substrates to which nucleotides can be polymerized by polymerases; however, in some embodiments, primers can become incorporated into a synthetic nucleic acid chain and provide a site to which another primer can hybridize to initiate the synthesis of a new chain complementary to a synthetic nucleic acid molecule. Primers can include any combination of nucleotides or their analogs. In some embodiments, primers are single-stranded oligonucleotides or polynucleotides. The terms "polynucleotide" and "oligonucleotide" are used interchangeably herein to refer to a polymeric form of nucleotides of any length, and may include ribonucleotides, deoxyribonucleotides, their analogs, or mixtures thereof. The term refers only to the primary structure of a molecule. Therefore, the term includes triple-stranded, double-stranded, and single-stranded deoxyribonucleic acids ("DNA"), as well as triple-stranded, double-stranded, and single-stranded ribonucleic acids ("RNA"). As used herein, "amplified target sequence" and its derivatives generally refer to a polynucleotide sequence generated by amplifying a target sequence using a target-specific primer and the method provided herein. The amplified target sequence can have the same sense sequence (ie, positive strand) or antisense sequence (ie, negative strand) relative to the target sequence.
[0051] As used herein, the term "polymerase" is intended to be consistent with its use in the art, and includes enzymes that, for example, use a polynucleotide as a template strand to produce a complementary replica of a polynucleotide. Typically, a DNA polymerase binds to a template strand and then moves downstream along the template strand, sequentially adding nucleotides to the free hydroxyl groups at the 3' end of the growing strand of the nucleic acid. DNA polymerases typically synthesize complementary DNA molecules from a DNA template, and RNA polymerases typically synthesize RNA molecules (transcription) from a DNA template. Polymerases can use short RNA or DNA chains known as primers to start chain growth. Some polymerases can displace the chain upstream of a site where a base is added to one of its chains. Such polymerases are referred to as chain displacement, meaning that they have the activity of removing complementary strands from a template strand read by a polymerase. Exemplary polymerases with chain displacement activity include, but are not limited to, large fragments of Bst (Bacillus stearothermophilus) polymerase, exo-Klenow polymerase, or sequencing-grade T7 exo-polymerases. Some polymerases degrade the strands in front of them, effectively replacing the strands in front with the growing strands behind (5' exonuclease activity). Some polymerases have activity that degrades the strand behind them (3' exonuclease activity). Some useful polymerases have been modified by mutation or otherwise to reduce or eliminate 3' exonuclease activity and / or 5' exonuclease activity.
[0052] As used herein, the term "universal sequence" refers to a region of a sequence common to two or more nucleic acid molecules, wherein these molecules also have regions of sequences that are different from each other. Universal sequences present in different members of a set of molecules can allow a population of universal capture nucleic acids complementary to the universal sequence to capture multiple different nucleic acids. Similarly, universal sequences present in different members of a set of molecules can allow a population of universal primers complementary to the universal sequence to replicate or amplify multiple different nucleic acids. Therefore, universal capture polynucleotides or universal primers include sequences that can specifically hybridize with universal sequences. Polynucleotides can be modified to attach universal adapters, for example, at one or both ends of different sequences.
[0053] Index Jump
[0054] The present disclosure relates particularly to sequencing polynucleotides from multiple indexed libraries; and more particularly, to increasing the likelihood that sequencing correctly identifies the library from which the polynucleotide originated.
[0055] When polynucleotides from different libraries are pooled or multiplexed for sequencing, the polynucleotides from each library can be modified to contain a library-specific index tag sequence. During sequencing, the index tag is sequenced together with the target polynucleotide sequence from the library. Thus, the index tag sequence can be associated with the target polynucleotide sequence so that the library from which the target sequence originated can be identified.
[0056] However, a phenomenon known as index hopping may occur in a small percentage of sequence results (typically 0.5% to 2%). Index hopping is when an index tag sequence from one library associates with a target polynucleotide from another library (see Fig. 6A and 6B ). Although the mechanism by which index jumping may occur is not fully understood, the rate of index jumping can be effectively reduced by blocking the 3' ends of unincorporated adapters after the adapters are attached to the target polynucleotides of the library, especially after the index tag sequence is attached to the polynucleotide.
[0057] Library sample preparation
[0058] A library comprising polynucleotides can be prepared in any suitable manner by attaching oligonucleotide adapters to target polynucleotides. As used herein, a "library" is a population of polynucleotides from a given source or sample. A library comprises more than one target polynucleotide. As used herein, a "target polynucleotide" is a polynucleotide that is desired to be sequenced. The target polynucleotide can be substantially any polynucleotide whose sequence is known or unknown. For example, the target polynucleotide can be a fragment of genomic DNA or cDNA. Sequencing can result in determination of the sequence of all or part of the target polynucleotide. The target polynucleotide can be derived from an initial polynucleotide sample that has been randomly fragmented. The target polynucleotide can be processed into a template suitable for amplification by placing a universal primer sequence at the end of each target fragment. The target polynucleotide can also be obtained by reverse transcription into cDNA from an initial RNA sample.
[0059] The terms "polynucleotide" and "oligonucleotide" are used interchangeably herein to refer to a polymeric form of nucleotides of any length, and may include ribonucleotides, deoxyribonucleotides, analogs thereof, or mixtures thereof. The term refers only to the primary structure of the molecule. Thus, the term includes triple-stranded, double-stranded, and single-stranded deoxyribonucleic acids ("DNA"), and triple-stranded, double-stranded, and single-stranded ribonucleic acids ("RNA"). The terms polynucleotide and oligonucleotide as used herein also include cDNA, which is a complementary or copy DNA produced from an RNA template, for example, by the action of a reverse transcriptase.
[0060] The initial polynucleotide molecule may be derived from a double-stranded DNA (dsDNA) form (e.g., genomic DNA fragments, PCR and amplification products, etc.), or may be derived from a single-stranded form of DNA or RNA and converted to a dsDNA form. For example, mRNA molecules may be copied into double-stranded cDNA using standard techniques well known in the art. The precise sequence of the initial polynucleotide is generally unimportant to the disclosure presented herein, and may be known or unknown.
[0061] In some embodiments, the initial target polynucleotide is an RNA molecule. In one aspect of such an embodiment, the RNA separated from a particular sample is first converted into double-stranded DNA using techniques known in the art. The double-stranded DNA can then be indexed and labeled with library-specific tags. Different preparations of such double-stranded DNA comprising library-specific index tags can be produced in parallel by RNA isolated from different sources or samples. Subsequently, different preparations of double-stranded DNA comprising different library-specific index tags can be mixed, all sequenced, and according to the presence of library-specific index tag sequences, the identity of each sequenced fragment is determined relative to the library separated / sourced from other.
[0062] In some embodiments, the initial target polynucleotide is a DNA molecule.For example, the initial polynucleotide can represent the entire genetic complementary sequence of an organism, and is a genomic DNA molecule, such as a human DNA molecule, which includes both introns and exon sequences (coding sequences), and non-coding regulatory sequences such as promoters and enhancer sequences.Although it is conceivable that a specific subset of a polynucleotide sequence or genomic DNA can also be used, such as, for example, a specific chromosome or a part thereof.In many embodiments, the sequence of the initial polynucleotide is unknown.Can be before or after a fragmentation process such as a random fragmentation process, and before, during or after connecting an adapter oligonucleotide, by chemical method or enzyme method process DNA target polynucleotide.
[0063] Preferably, the initial target polynucleotide is fragmented into a suitable length suitable for sequencing. The target polynucleotide can be fragmented in any suitable manner. Preferably, the target polynucleotide is randomly fragmented. Random fragmentation refers to that polynucleotide is fragmented in a disordered manner by, for example, enzymatic, chemical or mechanical means. Such fragmentation methods are known in the art, and standard methods (Sambrook and Russell, Molecular Cloning, A Laboratory Manual, 3rd edition) are used. For the sake of clarity, the smaller fragments of larger pieces of polynucleotides are amplified by specific PCR to produce such smaller fragments that are not equivalent to the larger pieces of nucleotides of fragmentation, because the larger pieces of polynucleotides remain intact (that is, not fragmented by PCR amplification). In addition, random fragmentation is designed to produce a fragment that does not consider the sequence identity or position of the nucleotides comprising fracture and / or near the fracture.
[0064] In some embodiments, random fragmentation is by mechanical means such as nebulization or sonication to produce fragments of about 50 base pairs in length to about 1500 base pairs in length, such as 50-700 base pairs in length or 50-500 base pairs in length.
[0065] The fragmentation of polynucleotide molecules by mechanical means (e.g., atomization, sonication, and Hydroshear) may result in fragments with a heterogeneous mixture of flat ends and 3'-overhanging ends and 5'-overhanging ends. The ends of the fragments can be repaired using methods known in the art or kits (such as the Lucigen DNA terminator end repair kit) to produce ends that are optimal for insertion, for example, into a flat site of a cloning vector. In some embodiments, the ends of the fragments of a population of polynucleotides are flat ends. The ends of the fragments can be flat-ended and phosphorylated. The phosphate moiety can be introduced by enzymatic treatment, for example, using polynucleotide kinase.
[0066] In some embodiments, the target polynucleotide is prepared to have a single overhanging nucleotide by, for example, the activity of certain types of DNA polymerases such as Taq polymerase or Klenow exominus polymerase (having non-template-dependent terminal transferase activity, adding a single deoxynucleotide, such as deoxyadenosine (A), to, for example, the 3' end of a PCR product). Such an enzyme can be used to add a single nucleotide "A" to the 3' end of the blunt end of each strand of the target polynucleotide duplex. Thus, by reacting the target polynucleotide duplex with Taq polymerase or Klenow exo minus polymerase, "A" can be added to the 3' end of each end-repaired duplex strand, and the adapter polynucleotide construct can be a compatible T-construct with the "T" overhang present at the 3' end of each duplex region of the adapter construct. This terminal modification also prevents self-ligation of the target polynucleotide, so that there is a bias towards forming a combined connected adapter-target polynucleotide.
[0067] In some embodiments, fragmentation is accomplished by tagmentation as described in, for example, International Patent Application Publication WO2016 / 130704. In such a method, a transposase is used to fragment a double-stranded polynucleotide. The resulting double-stranded fragments may be gap-filled as described in WO 2016 / 130704 and prepared for connection to an adaptor.
[0068] The target polynucleotide may include a 5'-phosphate portion remaining from the fragmentation process or added using an enzyme treatment step, and has been end-repaired, and optionally extended with one or more protruding bases to give a 3'-OH suitable for connection. In this article, attachment means the covalent connection of a polynucleotide chain that has not been covalently linked before. In a specific aspect of the present invention, such attachment occurs by forming a phosphodiester bond between two polynucleotide chains, but other means of covalent connection (e.g., non-phosphodiester backbone connection) may be used. Adapters are connected to target polynucleotides in more detail in, for example, U.S. Patent No. 8,053,192.
[0069] Fragmented polynucleotides that have been modified prior to ligation, for example to better prepare them for ligation, may be referred to herein as polynucleotide "fragments."
[0070] As used herein, the terms "ligating," "ligation," and their derivatives generally refer to the process of covalently linking two or more molecules together, such as covalently linking two or more polynucleotides to each other. In some embodiments, the connection includes a nick between adjacent nucleotides of the connecting polynucleotides. In some embodiments, the connection includes forming a covalent bond between the end of a first polynucleotide and the end of a second polynucleotide. In some embodiments, the connection may include forming a covalent bond between a 5' phosphate group of a nucleic acid and a 3' hydroxyl group of a second nucleic acid, thereby forming a connected polynucleotide. Typically for the purposes of the present disclosure, a target sequence may be linked to an adaptor to produce an adaptor-linked target sequence.
[0071] As used herein, "ligase" and its derivatives generally refer to any agent capable of catalyzing the connection of two substrate molecules. In some embodiments, ligases include enzymes capable of catalyzing the connection of nicks between adjacent nucleotides of a nucleic acid. In some embodiments, ligases include enzymes capable of catalyzing the formation of a covalent bond between a 5' phosphate of a nucleic acid molecule and a 3' hydroxyl of another nucleic acid molecule to form a connected nucleic acid molecule. Suitable ligases may include, but are not limited to, T4 DNA ligase, T4 RNA ligase, and E. coli DNA ligase.
[0072] As used herein, "connection conditions" and their derivatives generally refer to conditions suitable for connecting two molecules to each other. In some embodiments, the connection conditions are suitable for closing the nick or gap between nucleic acids. As used herein, the term nick or gap is consistent with the use of the term in the art. Typically, the nick or gap can be connected at an appropriate temperature and pH in the presence of an enzyme such as a ligase. In some embodiments, T4 DNA ligase can connect the nick between nucleic acids at a temperature of about 70°C-72°C.
[0073] Any suitable adapter can be connected to the target polynucleotide. Preferably, the adapter includes a first oligonucleotide chain with a 5' end and a 3' end and a second oligonucleotide chain with a 5' end and a 3' end. The region at the 5' end of the first chain contains nucleotides complementary to the nucleotides in the region at the 3' end of the second chain, so that the complementary region is double-stranded. The region at the 3' end of the first chain and the region at the 5' end of the second chain are non-complementary enough to become single-stranded.
[0074] Preferably, the double-stranded region of the adapter is as short as possible without losing function. In this context, "function" refers to the ability of the double-stranded region to form a stable duplex under standard reaction conditions. In some embodiments, standard reaction conditions refer to the reaction conditions for the polynucleotide ligation reaction catalyzed by enzymes, which will be well known to the skilled reader (for example, incubated in a connection buffer suitable for enzymes at a temperature in the range of 4 ° C to 25 ° C), so that the two chains forming the adapter are kept partially annealed during the connection of the adapter to the target molecule. The connection method is known in the art, and standard methods (Sambrook and Russell, Molecular Cloning, A Laboratory Manual, 3rd edition) can be used. Such methods use ligases such as DNA ligases to achieve or catalyze the connection of the ends of the two polynucleotide chains of the adapter duplex oligonucleotide and the target polynucleotide duplex in this case, so that covalent connection is formed. The adapter duplex oligonucleotide can include a 5'-phosphate moiety to facilitate connection to the target polynucleotide 3'-OH.
[0075] The double-stranded region of the adapter can have any suitable number of base pairs. Preferably, the double-stranded region is a short double-stranded region formed by annealing of two partially complementary polynucleotide chains, typically comprising 5 or more continuous base pairs. Such a "double-stranded region" of the adapter refers to the region where the two chains anneal, and does not imply any specific structural conformation. In some embodiments, the double-stranded region comprises 20 or less continuous base pairs, such as 10 or less or 5 or less continuous base pairs.
[0076] The stability of the double stranded region may be increased by including non-natural nucleotides that exhibit stronger base pairing than standard Watson-Crick base pairs, and thus its length may be reduced. Preferably, the two strands of the adaptor are 100% complementary in the double stranded region.
[0077] When the adaptor is attached to the target polynucleotide, the non-complementary single-stranded region can form the 5' end and the 3' end of the polynucleotide to be sequenced. The term "non-complementary single-stranded region" refers to a region of the adaptor where the sequences of the two polynucleotide chains forming the adaptor exhibit a degree of non-complementarity such that the two chains are unable to completely anneal to each other under standard annealing conditions used for PCR reactions.
[0078] The non-complementary single-stranded region is provided by the different parts of the identical two polynucleotide chains forming the double-stranded region. The lower limit of the length of the single-stranded portion will be determined by the function of the suitable sequence of the combination of the primers for primer extension, PCR and / or sequencing, for example. In theory, there is no upper limit of the length of the region that does not match, except that the total length of the adapter is usually minimized, for example, to promote that the unbound adapter is separated from the adapter-target construct after one or more attachment steps is advantageous. Therefore, it is usually preferred that the non-complementary single-stranded region length of the adapter is 50 or less continuous nucleotides, such as a length of 40 or less, 30 or less or 25 or less continuous nucleotides.
[0079] The single-stranded ends of the adaptors are modified to prevent digestion by exonucleases. For example, the 3' end can be modified to prevent digestion by a 3' exonuclease, and the 5' end can be modified to prevent digestion by a 5' exonuclease. For purposes of the present disclosure, a modification that "prevents" digestion by an exonuclease inhibits the activity of the exonuclease relative to its action on the unmodified end. Preferably, the modification that prevents digestion by an exonuclease eliminates the ability of the exonuclease to digest the polynucleotide chain.
[0080] The free end of the single-stranded region of the adapter can be modified in any suitable manner to prevent exonuclease activity. In some embodiments, the free end of the single-stranded region of the adapter comprises a phosphorothioate bond. Preferably, the bond between the terminal three nucleotides of the free end of the single-stranded region of the adapter comprises a phosphorothioate bond. For the purposes of the present disclosure, the end of a polynucleotide whose bond between its terminal three nucleotides comprises a phosphorothioate bond can be referred to as an end comprising three phosphorothioate bonds. As is well known in the art, a phosphorothioate bond can be introduced into the 5' end or 3' end of a polynucleotide in any suitable manner. Oligonucleotides comprising terminal phosphorothioate bonds can be purchased from many commercial suppliers, including, for example, Integrated DNA Technologies and Sigma-Aldrich.
[0081] In some embodiments, a single-stranded DNA binding protein (SSB) binds to the free ends of the single-stranded regions of the adaptors to protect the free ends of the adaptors from exonuclease degradation. Any suitable SSB can be used to bind to the single-stranded regions of the adaptors to protect the single-stranded regions from exonuclease activity.Examples of suitable SSBs include herpes simplex virus (HSV-1) SSB (Mapelli M, Panjikar S, Tucker PA (2005). "The crystal structure of the herpes simplex virus 1ssDNA-binding protein suggests the structural basis for flexible, cooperative single-stranded DNA binding". J Biol Chem. 280(4): 2990-7); Escherichia coli SSB (Meyer RR, Laine PS (December 1990). "The single-stranded DNA-binding protein of Escherichia coli". Microbiol. Rev. 54(4): 342-80); eukaryotic mitochondrial SSB, such as human mitochondrial SSB (mtSSB) (Tiranti, V; Rocchi, M; DiDonato, S; Zeviani, M (April 30, 1993). "Cloning of human and rat cDNAs encoding the mitochondrial single-strandedDNA-binding protein (SSB)". Gene. 126 (2): 219-25) and Saccharomyces cerevisiae SSB (Van Dyck, E; Foury, F; Stillman, B; Brill, SJ (September 1992). "A single-stranded DNA binding protein required for mitochondrial DNA replication in S. cerevisiae is homologous to E. coli SSB". The EMBO Journal. 11 (9): 3421-30); and eukaryotic replication protein A (Wold, MS (1997). "Replication protein A: heterotrimeric, single-stranded DNA-binding protein required for eukaryotic DNA metabolism". Annual Review of Biochemistry. 66 (1): 61-92).SSB is commercially available from a number of suppliers including ThermoFisherScientific (Cat. No. 70032Z500UG) and Sigma-Aldrich (MDL No. MFCD00213047).
[0082] SSB can bind to the single-stranded free ends of the adapter before, during or after the adapter is connected to the target polynucleotide. If the bound SSB interferes with the ligation reaction, the SSB preferably binds to the single-stranded free ends of the adapter after the adapter is connected to the target polynucleotide. After the adapter is connected to the target polynucleotide, the following types of polynucleotides may remain: adapter, adapter-target and adapter-target-adapter. The single-stranded free ends of the adapter will be protected from exonuclease activity due to binding SSB, while the double-stranded regions of the adapter and adapter-target molecules will be susceptible to exonuclease activity. After exonuclease degradation, the adapter-target-adapter with bound SSB will still exist. Before hybridizing the adapter-target-adapter polynucleotide with a solid surface having an oligonucleotide complementary to at least one sequence of the free ends of the adapter, the SSB can be removed to promote hybridization. SSB can be removed in any suitable manner. For example, SSB can be removed under denaturing conditions.
[0083] In some embodiments, the free end of the single-stranded region of the adaptor includes a biotin group, and avidin or streptavidin can bind to the biotin group to prevent degradation by exonucleases. Biotin can be attached to the free 5' end and 3' end of the adaptor in any suitable manner. For example, biotin can be incorporated into the 5' end or 3' end of the adaptor by enzymatic incorporation of biotin-labeled nucleotides, by chemical modification of the 5' end or 3' end of the biotin-attached oligonucleotide primer, by using a labeled oligonucleotide primer, etc. For example, biotin can be incorporated into the 3' end using, for example, terminal deoxynucleotidyl transferase (TdT), which catalyzes the non-template-directed nucleotide incorporation of biotinylated nucleotides into the 3'-OH end of single-stranded DNA. One example of a kit for attaching biotin to the 3' end of the free end of an adaptor is the ThermoScientific Pierce Biotin 3' End Labeling Kit (Cat. No. 89818), which uses TdT to incorporate 1-3 biotinylated ribonucleotides (biotin-11-UTP) into the 3' end of single-stranded DNA.
[0084] Biotin-labeled nucleotides may contain a cleavable linker, such as a disulfide bond, which can be cleaved, for example, by dithiothreitol to release biotin (and any avidin or streptavidin). Biotin labels with cleavable linkers, including biotin-labeled nucleotides with cleavable linkers, are commercially available from a number of suppliers, such as Integrated DNA Technologies, Inc. (IDT) of Skokie, IL.
[0085] Avidin or streptavidin can be bound to the adaptor before, during or after the adaptor is connected to the target polynucleotide. If the bound avidin or streptavidin interferes with the ligation reaction, it is preferred that the avidin or streptavidin is bound to the single-stranded free end of the adaptor after the adaptor is connected to the target polynucleotide. After the adaptor is connected to the target polynucleotide, the following types of polynucleotides may remain: adaptor, adaptor-target and adaptor-target-adaptor. The single-stranded free end of the adaptor will be protected from exonuclease activity due to binding avidin or streptavidin, while the double-stranded region of the adaptor and the adaptor-target molecule will be susceptible to exonuclease activity. After exonuclease degradation, the adaptor-target-adaptor with bound avidin or streptavidin will still exist. Prior to hybridizing the adapter-target-adapter polynucleotide to a solid surface having an oligonucleotide complementary to at least one sequence of the free end of the adapter, the avidin or streptavidin may be removed to facilitate hybridization. The avidin or streptavidin may be removed in any suitable manner. Preferably, the biotin label comprises a cleavable linker that allows removal of biotin and bound avidin or streptavidin.
[0086] In some embodiments, the free ends of the single-stranded region of the adaptor are bound by antibodies against the Y-shaped adaptor to prevent degradation by exonucleases from the 5' and 3' single-stranded ends of the adaptor.
[0087] Preferably, the ends of the double stranded region of the adaptor forming the adaptor are susceptible to exonuclease activity. Preferably, the ends of the double stranded region of the adaptor forming the adaptor are at least as susceptible to exonuclease activity as the ends comprising unmodified nucleotides. In some embodiments, the ends of the double stranded region of the adaptor forming the adaptor comprise unmodified nucleotides.
[0088] Individual strands of the oligonucleotides can be mixed and annealed to generate adaptors having double-stranded portions and single-stranded portions in order to ligate the double-stranded portion to the double-stranded target fragment.
[0089] At least one of the first or second chains forming the adapter includes a library-specific index tag sequence. Before the sample is fixed for sequencing, the index tag sequence can be attached to the target polynucleotide from each library by connecting the adapter to the target. The index tag itself is not formed by a part of the target polynucleotide, but becomes a part of the template for amplification. The index tag can be a synthetic nucleotide sequence added to the target as part of the template preparation step. Therefore, the library-specific index tag is a nucleic acid sequence tag attached to each target molecule of a specific library, and its presence indicates or is used to identify the library from which the target molecule is separated.
[0090] Preferably, the index tag sequence length is 20 nucleotides or less. For example, the index tag sequence length can be 1-10 nucleotides or 4-6 nucleotides. Tetranucleotide index tags provide the possibility of multiplexing 256 samples on the same array, and hexanucleotide index tags enable 4096 samples to be processed on the same array. The adapter can contain more than one index tag, so that the multiplexing possibility can be increased.
[0091] The library-specific index tag sequence can be located in the single-stranded region, the double-stranded region, or spans the single-stranded and double-stranded regions of the adaptor. Preferably, the index tag sequence is in the single-stranded region of the adaptor.
[0092] The adapter can include any other suitable sequence except the index tag sequence. For example, the adapter can include a universal extension primer sequence, which is generally located at the 5' end or 3' end of the adapter and the resulting polynucleotide for sequencing. The universal extension primer sequence can be hybridized with a complementary primer that is bound to a solid substrate surface. The complementary primer includes a free 3' end, and a polymerase or other suitable enzyme can use the hybridized library polynucleotide as a template to add nucleotides from the free 3' end to extend the sequence, causing the reverse strand of the library polynucleotide to be coupled to the solid surface. Such an extension can be a part of a sequencing run or cluster amplification.
[0093] In some embodiments, the adaptor comprises one or more universal sequencing primer sequences. The universal sequencing primer sequence can be combined with a sequencing primer to allow sequencing of the index tag sequence, the target sequence, or both the index tag sequence and the target sequence.
[0094] The precise nucleotide sequence of the adaptors is generally unimportant to the invention and can be selected by the user so that the desired sequence elements are ultimately included in the consensus sequence of a library of templates obtained from the adaptors, which, for example, provide binding sites for a particular set of universal extension primers and / or sequencing primers.
[0095] Preferably, the adapter is attached to both ends of the target polynucleotide to produce a polynucleotide having a first adapter-target-second adapter nucleotide sequence. The first adapter and the second adapter can be the same or different. Preferably, the first adapter and the second adapter are the same. In such an embodiment, the resulting polynucleotide will have a first adapter-target-first adapter nucleotide sequence. If the first adapter and the second adapter are different, at least one of the first adapter and the second adapter comprises a library-specific index tag sequence.
[0096] It will be understood that a "first adapter-target-second adapter sequence", "first adapter-target-first adapter sequence" or "adapter-target-adapter" sequence refers to the orientation of the adapters relative to each other and to the target, and does not necessarily mean that the sequence may not include additional sequences, such as, for example, linker sequences.
[0097] Additional libraries can be prepared in a similar manner, each library comprising at least one library-specific index tag sequence or combination of index tag sequences that is different from index tag sequences or combinations of index tags from other libraries.
[0098] After the adapter is attached to the target polynucleotide, the resulting polynucleotide can be subjected to a cleaning process to enhance the purity of the adapter-target-adapter polynucleotide by removing at least a portion of the unincorporated adapter. Any suitable cleaning process can be used, such as electrophoresis, size exclusion chromatography, etc. In some embodiments, solid phase reverse immobilization (SPRI) paramagnetic beads can be used to separate the adapter-target-adapter polynucleotide from the unattached adapter. Although such a method can enhance the purity of the resulting adapter-target-adapter polynucleotide, some unattached adapter oligonucleotides may be retained.
[0099] The clean-up process can be performed on each individual library or on the pooled libraries.
[0100] Exonuclease treatment
[0101] The solution or composition comprising the resulting adapter-target-adapter polynucleotide, whether or not first subjected to cleanup, along with any unincorporated adapter oligonucleotides or target polynucleotides, is treated with an exonuclease to digest polynucleotides having an unprotected 5' end or an unprotected 3' end, including unincorporated adapters.
[0102] Any suitable exonuclease can be used. Preferably, the exonuclease has 5' exonuclease activity and 3' exonuclease activity. An exonuclease with "5' exonuclease activity" is an exonuclease that digests DNA in the 5' to 3' direction. An exonuclease with "3' exonuclease activity" is an exonuclease that digests DNA in the 3' to 5' direction. The exonuclease may include activity against unnicked double-stranded DNA. An example of a suitable exonuclease with 5' exonuclease activity and 3' exonuclease activity and activity against unnicked double-stranded DNA is Exonuclease V, which is a RecBCD complex from Escherichia coli and is available, for example, from New England Biolabs (Cat#M0345S / L).
[0103] In some embodiments, two exonucleases can be used, one with 5' exonuclease activity and the other with 3' exonuclease activity. Examples of exonucleases with 5' exonuclease activity include lambda exonuclease (New England Biolabs) and truncated exonuclease VIII (New England Biolabs). An example of an exonuclease with 3' exonuclease activity is exonuclease T (New England Biolabs).
[0104] The exonuclease treatment can be performed on each library individually, or on the pooled libraries. After the exonuclease treatment, a clean-up step such as described above can be performed, and then the polynucleotides are immobilized on a solid surface for sequencing.
[0105] If the libraries have not yet been pooled, they can be pooled prior to immobilization on the sequencing surface.
[0106] Preparation of fixed samples for sequencing
[0107] The exonuclease-treated library preparations collected can then be fixed on a solid surface in preparation for sequencing. Sequencing can be performed with a single molecule array, or can be amplified before sequencing. Amplification can be implemented using one or more immobilized primers. One or more immobilized primers can be a lawn on a planar surface, a cluster on a planar surface, in a hole in a porous structure, on a pool of beads, etc. The pool of beads can be separated into emulsions, and in each "compartment" of the emulsion, there is a single bead. At the concentration of only one template in each "compartment", only a single template is amplified on each bead.
[0108] The term "solid phase amplification" as used herein refers to any polynucleotide amplification reaction implemented on a solid support or in association with a solid support, so that all or a portion of the amplified products are fixed on the solid support when they are formed. In particular, the term includes solid phase polymerase chain reaction (solid phase PCR) and solid phase isothermal amplification, which is a reaction similar to standard solution phase amplification, except that one or both of the forward amplification primer and the reverse amplification primer are fixed on the solid support. Solid phase PCR covers systems, such as an emulsion in which one primer is anchored to a bead and another in a free solution, and a clone (colony) is formed in a solid phase gel matrix, in which one primer is anchored to a surface and one in a free solution.
[0109] Although the present disclosure includes a "solid phase" amplification method in which only one amplification primer is fixed (another primer is usually present in free solution), it is preferred to provide fixed forward primers and reverse primers to a solid support. In practice, because the amplification process requires excessive primers to maintain amplification, "more than one" identical forward primers and / or "more than one" identical reverse primers will be fixed on the solid support. Unless the context indicates otherwise, forward primers and reverse primers mentioned herein will be correspondingly interpreted as including "more than one" such primers.
[0110] As the skilled technical reader will appreciate, any given amplification reaction requires at least one type of forward primer and at least one type of reverse primer to be treated for template specific amplification. However, in certain embodiments, forward primer and reverse primer can comprise the template specific portion of the same sequence, and can have identical nucleotide sequence and structure (comprising any non-nucleotide modification). In other words, it is possible to implement solid phase amplification using only one type of primer, and such single primer method is included within the scope of the present invention. Other embodiments can use forward primer and reverse primer comprising the same template specific sequence but some of its other structural features are different. For example, one type of primer can comprise non-nucleotide modification not present in the primer of another type.
[0111] Throughout this disclosure, the terms "P5" and "P7" are used when referring to adapters and / or amplification primers. It will be understood that any suitable amplification primer can be used in the methods shown herein, and the use of P5 and P7 is only an exemplary embodiment. The use of amplification primers such as P5 and P7 on a flow cell is known in the art, as illustrated by the disclosures of WO 2007 / 010251, WO 2006 / 064199, WO 2005 / 065814, WO 2015 / 106941, WO 1998 / 044151, and WO 2000 / 018957, each of which is incorporated by reference in its entirety. For example, any suitable forward amplification primer, whether fixed or in solution, can be used in the methods shown herein for hybridization with complementary sequences and amplification sequences. Similarly, any suitable reverse amplification primer, whether fixed or in solution, can be used in the methods shown herein for hybridization with complementary sequences and amplification sequences. Those skilled in the art will understand how to design and use primer sequences suitable for capturing and amplifying nucleic acids as presented herein.
[0112] Primers for solid phase amplification are preferably fixed by covalent attachment to a solid support single point at or near the 5' end of the primer, so that the template-specific portion of the primer is freely annealed to its associated template and the 3' hydroxyl group is free for primer extension. Any suitable covalent attachment means known in the art can be used for this purpose. The attachment chemistry selected will depend on the properties of the solid support, as well as any derivatization or functionalization applied to it. The primer itself can include a part that can be a non-nucleotide chemical modification to promote attachment. In some embodiments, the primer includes a sulfur-containing nucleophile at the 5' end, such as thiophosphate (phosphorothioate) or thiophosphate (thiophosphate). The surface of the solid support can include or be modified to include a part that includes a sulfur-containing nucleophile that can be attached. For example, a sulfur-containing nucleophile can be combined with a bromoacetamide group. In some embodiments, the polyacrylamide hydrogel of the solid support includes a bromoacetamide group for combining a sulfur-containing nucleophile. A more particular means of attaching the primers and template to the solid support is by 5' phosphorothioate attachment to a hydrogel comprising polymerized acrylamide and N-(5-bromoacetamidopentyl)acrylamide (BRAPA), as fully described in WO / 2005065814.
[0113] Solid supports comprising inert substrates or matrix (e.g., slides, polymer beads, etc.) can be, for example, "functionalized" by applying an intermediate material layer or coating comprising a reactive group, which allows covalent attachment to biomolecules such as polynucleotides. Examples of such supports include, but are not limited to, polyacrylamide hydrogels supported on inert substrates such as glass. In such embodiments, biomolecules (e.g., polynucleotides) can be directly covalently attached to intermediate materials (e.g., hydrogels), but intermediate materials themselves can be non-covalently attached to substrates or matrix (e.g., glass substrates). The term "covalently attached to a solid support" will be understood to include this type of arrangement accordingly.
[0114] The library samples collected can be amplified on a solid surface comprising forward and reverse amplification primers. In some embodiments, the library collected by polynucleotide is used for the array of clustering of polynucleotide clones prepared by solid phase amplification and more particularly by solid phase isothermal amplification, similar to those described in U.S. Patent Publication No. 2005 / 0100900, U.S. Patent No. 7,115,400, WO 00 / 18957 and WO98 / 44151. The terms "cluster" and "clone" are used interchangeably herein to refer to discrete sites comprising more than one identical fixed nucleic acid chain and more than one identical fixed complementary nucleic acid chain on a solid support. The term "clustered array" refers to an array formed by such a cluster or clone. In this article, the term "array" should not be construed as requiring the orderly arrangement of clusters.
[0115] The terms solid phase or surface are used to mean a planar array (in which primers are attached to a flat surface, e.g., a glass, silica, or plastic microscope slide) or a similar flow cell device; beads, in which one or two primers are attached to the beads and the beads are amplified; an array of beads on a surface (after the beads have been amplified), etc.
[0116] The terms "solid surface," "solid support," and other grammatical equivalents herein refer to any material that is suitable or can be modified to be suitable for attachment of a template polynucleotide. As will be appreciated by those skilled in the art, the number of possible substrates is extremely large. Possible substrates include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylic, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethane, The solid supports and solid surfaces particularly useful for some embodiments are located within a flow cell device. Exemplary flow cells are described in more detail below.
[0117] In some embodiments, the solid support comprises a patterned surface." patterned surface " refers to the arrangement of different regions in the layer exposed by the solid support or on the exposed layer. For example, one or more regions can be the feature in which one or more amplification primers are present. The feature can be separated by the gap region in which there is no amplification primer. In some embodiments, the pattern can be the feature of the xy format in rows and columns. In some embodiments, the pattern can be the repeated arrangement of the feature and / or gap region. In some embodiments, the pattern can be the random arrangement of the feature and / or gap region. The exemplary patterned surface that can be used for the method and composition set forth herein is described in U.S. Patent No. 8,778,848, No. 8,778,849, No. 9,079,148 and U.S. Publication No. 2014 / 0243224.
[0118] In some embodiments, the solid support includes an array of holes or depressions in the surface. As is generally known in the art, this can be manufactured using a variety of techniques including, but not limited to, photolithography, stamping techniques, molding techniques, and microetching techniques. As will be understood by those skilled in the art, the techniques used will depend on the composition and shape of the array substrate.
[0119] The features in the patterned surface can be holes (e.g., micropores or nanopores) in an array of holes on a glass, silicon, plastic or other suitable solid support with a patterned, covalently attached gel, such as poly (N- (5-azidoacetamidopentyl) acrylamide-co-acrylamide) (PAZAM, see, e.g., U.S. Publication Nos. 2013 / 184796, WO 2016 / 066586, and WO 2015 / 002813). The process produces a gel pad for sequencing that can be stable over a large number of cycles of sequencing runs. The covalent attachment of the polymer to the hole helps maintain the gel in the structured features throughout the life of the structured substrate during a variety of uses. However, in many embodiments, the gel does not have to be covalently attached to the hole. For example, under some conditions, a silane-free acrylamide (SFA, see, e.g., U.S. Patent No. 8,563,477) that is not covalently attached to any portion of the structured substrate can be used as the gel material.
[0120] In certain embodiments, the solid support material can be patterned with holes (e.g., micropores or nanopores), the patterned support can be coated with a gel material (e.g., PAZAM, SFA, or a chemically modified variant thereof, such as an azidized form of SFA (azido-SFA)), and the gel-coated support can be polished, for example, by chemical or mechanical polishing, so that the gel is retained in the holes, but substantially all of the gel in the interstitial regions between the holes on the surface of the structured substrate is removed or substantially all of the gel is inactivated. Primer nucleic acids can be attached to the gel material. Then a solution of target nucleic acids (e.g., a fragmented human genome) can be contacted with the polished substrate so that individual target nucleic acids will inoculate individual holes by interacting with primers attached to the gel material; however, due to the absence or inactivity of the gel material, the target nucleic acid will not occupy the interstitial region. The amplification of the target nucleic acid will be limited to the holes because the absence or inactivity of the gel in the interstitial region prevents the outward migration of the growing nucleic acid clones. The process is conveniently manufacturable, can be scaled up, and conventional micro or nano manufacturing methods can be used. As used herein, the term "flow cell" refers to a chamber comprising a solid surface across which one or more fluid reagents can flow. Examples of flow cells and associated fluid systems and detection platforms that can be readily used in the methods of the present disclosure are described below: e.g., Bentley et al., Nature 456:53-59 (2008); WO 04 / 018497; US 7,057,026; WO 91 / 06678; WO 07 / 123744; US 7,329,492; US 7,211,414; US 7,315,019; US 7,405,281 and US 2008 / 0108082.
[0121] In some embodiments, the solid support or its surface is non-planar, such as the inner or outer surface of a tube or container. In some embodiments, the solid support includes microspheres or beads. "Microspheres" or "beads" or "particles" or grammatical equivalents herein refer to small discrete particles. Suitable bead components include but are not limited to plastics, ceramics, glass, polystyrene, methyl styrene, acrylic polymers, paramagnetic materials, thoria sols, carbon graphite, titanium dioxide, latex or cross-linked dextran such as Sepharose, cellulose, nylon, cross-linked micelles and teflon and any other material for solid supports outlined herein can be used. "Microsphere Detection Guide" from Bangs Laboratories, Fishers Ind. is a useful guide. In certain embodiments, the microsphere is a magnetic microsphere or bead.
[0122] The beads need not be spherical; irregular particles may be used. Alternatively or additionally, the beads may be porous. Bead sizes range from nanometers, i.e., 100 nm, to millimeters, i.e., 1 mm, with beads from about 0.2 microns to about 200 microns being preferred, and beads from about 0.5 microns to about 5 microns being particularly preferred, although in some embodiments, smaller or larger beads may be used.
[0123] Clustered arrays can be prepared using a thermal cycling process as described in WO / 9844151 or a process wherein the temperature is maintained constant and a change in reagents is used to carry out a cycle of extension and denaturation. Such isothermal amplification methods are described in patent applications No. WO / 0246456 and No. US 2008 / 0009420. This is particularly preferred due to the requirement for lower temperatures in the isothermal process.
[0124] It will be appreciated that any amplification method described herein or generally known in the art can be used with universal primers or target-specific primers to amplify fixed DNA fragments. Suitable methods for amplification include but are not limited to polymerase chain reaction (PCR), strand displacement amplification (SDA), transcription-mediated amplification (TMA) and amplification based on nucleic acid sequence (NASBA), as described in U.S. Patent No. 8,003,354, which is incorporated herein by reference in its entirety. The above amplification method can be used to amplify one or more nucleic acids of interest. For example, PCR includes multiple PCR, SDA, TMA, NASBA, etc. can be used to amplify fixed DNA fragments. In some embodiments, primers specifically for polynucleic acids of interest are included in the amplification reaction.
[0125] Other suitable methods for amplifying polynucleotides can include oligonucleotide extension and ligation, rolling circle amplification (RCA) (Lizardi et al., Nat. Genet. 19: 225-232 (1998)) and oligonucleotide ligation assay (OLA) (see generally U.S. Patent Nos. 7,582,420, 5,185,243, 5,679,524 and 5,573,907; EP 0 320308B1; EP 0 336 731B1; EP 0 439182B1; WO 90 / 01069; WO 89 / 12696; and WO 89 / 09835) techniques. It will be appreciated that these amplification methods can be designed to amplify fixed DNA fragments. For example, in some embodiments, the amplification method can include ligation probe amplification or oligonucleotide ligation assay (OLA) reactions, which include primers specifically for the nucleic acid of interest. In some embodiments, the amplification method may include a primer extension-ligation reaction including primers specific for the nucleic acid of interest. As a non-limiting example of primer extension and ligation primers that can be specifically designed to amplify the nucleic acid of interest, the amplification may include primers for GoldenGate assay (Illumina, Inc., San Diego, CA), as exemplified by U.S. Patents Nos. 7,582,420 and 7,611,869.
[0126] Exemplary isothermal amplification methods that can be used in the methods of the present disclosure include, but are not limited to, multiple displacement amplification (MDA) as exemplified by, e.g., Dean et al. Proc. Natl. Acad. Sci. USA 99:5261-66 (2002), or isothermal strand displacement nucleic acid amplification as exemplified by, e.g., U.S. Pat. No. 6,214,587. Other non-PCR-based methods that can be used in the present disclosure include, for example, Walker et al., Molecular Methods for Virus Detection, Academic Press, Inc., 1995; U.S. Pat. Nos. 5,455,166 and 5,130,238, and Walker et al., Nucl. Acids Res. 20:1691-96 (1992) described in strand displacement amplification (SDA), or hyper-branched strand displacement amplification described in, for example, Lage et al., Genome Res. 13:294-307 (2003). For random primer amplification of genomic DNA, isothermal amplification methods can be used with strand displacement Phi 29 polymerase or Bst DNA polymerase large fragment, 5'->3'exo-. The use of these polymerases takes advantage of their high processivity and strand displacement activity. High processivity allows the polymerase to produce fragments of 10kb-20kb in length. As set forth above, smaller fragments can be generated under isothermal conditions using a polymerase with low processivity and strand displacement activity, such as Klenow polymerase.Additional description of amplification reactions, conditions, and components are set forth in detail in the disclosure of U.S. Pat. No. 7,670,810, which is incorporated herein by reference in its entirety.
[0127] Another nucleic acid amplification method useful in the present disclosure is Tagged PCR, which uses a population of two-domain primers with a constant 5' region followed by a random 3' region, as described, for example, in Grothues et al. Nucleic Acids Res. 21(5): 1321-2 (1993). The first multiple rounds of amplification are performed to allow a large number of starts based on hybridization from the randomly synthesized 3' region alone on heat-denatured DNA. Due to the nature of the 3' region, the start site is expected to be random across the genome. Thereafter, unbound primers can be removed and additional replication can occur using primers complementary to the constant 5' region.
[0128] In some embodiments, isothermal amplification can be carried out using the kinetic exclusion amplification (KEA) also referred to as exclusion amplification (ExAmp). The nucleic acid library of the present disclosure can be prepared using a method comprising reacting an amplification reagent to produce a step more than one amplification site, each of which comprises a substantially clonal population of the amplicon from the independent target nucleic acid inoculated in the site. In some embodiments, the amplification reaction proceeds to produce a sufficient number of amplicon to fill the capacity of the corresponding amplification site. Filling the site inoculated in this way to the capacity suppresses the landing and amplification of the target nucleic acid at the site, thereby producing a clonal population of the amplicon at the site. In some embodiments, even if the amplification site is not filled to the capacity before the second target nucleic acid arrives at the site, it is also possible to realize apparent clonality. Under some conditions, the amplification of the first target nucleic acid can proceed to a sufficient number of copies to be produced to effectively outperform or overwhelm the point produced from the copy of the second target nucleic acid transported to the site. For example, in an embodiment using a bridge amplification process for circular features less than 500 nm in diameter, it has been determined that after 14 cycles of exponential amplification of a first target nucleic acid, contamination from a second target nucleic acid at the same site will produce insufficient numbers of contaminating amplicons to adversely affect sequencing-by-synthesis analysis on an Illumina sequencing platform.
[0129] As demonstrated by the above examples, in a particular embodiment, the amplification sites in the array can be but need not be completely cloned. Rather, for some applications, the individual amplification sites can be mainly populated with the amplicon from the first target nucleic acid, and can also have low-level contamination amplicon from the second target nucleic acid. As long as the contamination level does not have an unacceptable impact on the subsequent use of the array, the array can have one or more amplification sites with low-level contamination amplicon. For example, when the array will be used in a detection application, an acceptable contamination level will be a level that will not affect the signal-to-noise ratio or resolution of the detection technology in an unacceptable manner. Therefore, apparent clonality will generally be related to the specific use or application of the array made by the method set forth herein. Exemplary contamination levels that can be accepted at the individual amplification sites for specific applications include but are not limited to at most 0.1%, 0.5%, 1%, 5%, 10% or 25% contamination amplicon. The array can include one or more amplification sites with the contamination amplicon of these exemplary levels. For example, up to 5%, 10%, 25%, 50%, 75% or even 100% of the amplification sites in the array can have some contamination amplicon. It will be appreciated that at least 50%, 75%, 80%, 85%, 90%, 95%, or 99% or more of the sites in an array or other collection of sites may be clonal or apparent clonal.
[0130] In some embodiments, kinetic exclusion can occur in a process when a sufficiently fast rate occurs to effectively exclude another event or process. Taking the preparation of nucleic acid array as an example, the site of the array is randomly inoculated with the target nucleic acid from the solution, and a copy of the target nucleic acid is produced in the amplification process to fill each inoculated site to capacity. According to the kinetic exclusion method of the present disclosure, inoculation and amplification process can be carried out simultaneously under the condition that the amplification rate exceeds the inoculation rate. Therefore, the relatively fast rate of copying at the site inoculated by the first target nucleic acid will effectively exclude the second nucleic acid inoculation site for amplification. Kinetic exclusion amplification method can be carried out as described in detail in No. 2013 / 0338042 of the U.S. Publication, which is incorporated herein by reference in its entirety.
[0131] Kinetics excludes the relatively fast rate of the subsequent copy of the target nucleic acid (or the first copy of the target nucleic acid) that can be utilized to amplify the initial relatively slow rate (for example, the slow rate of preparing the first copy of the target nucleic acid) contrast preparation.In the example of the previous paragraph, the occurrence of kinetics excludes the relatively fast rate of the subsequent copy of the target nucleic acid (or the first copy of the target nucleic acid) due to the relatively slow rate (for example, relatively slow diffusion or transport) of the target nucleic acid inoculation contrast amplification occurs to fill the site with a copy of the nucleic acid seed.In another exemplary embodiment, the occurrence of kinetics excludes can be due to the delay (for example, delayed or slow activation) of the formation of the first copy of the target nucleic acid inoculated site contrast preparation to copy to fill the site.In this example, a single site may have been inoculated with several different target nucleic acids (for example, several target nucleic acids can be present in each site before amplification).However, for any given target nucleic acid, the first copy formation can be randomly activated, so that the average rate of the first copy formation is relatively slow compared with the rate of producing the subsequent copy.In this case, although a single site may have been inoculated with several different target nucleic acids, kinetics excludes the one that will only allow those target nucleic acids to be amplified. More specifically, after a first target nucleic acid has been activated for amplification, the site will quickly be filled to capacity with copies of the first target nucleic acid, thereby preventing copies of the second target nucleic acid from being made at the site.
[0132] Amplification reagents can include additional components that promote amplicon formation and increase the rate of amplicon formation in some cases. An example is a recombinase. Recombinases can promote amplicon formation by allowing repeated invasion / extension. More specifically, recombinases can promote the invasion of target nucleic acids by polymerases, and use target nucleic acids as templates for amplicon formation by polymerase extension primers. This process can be repeated as a chain reaction, wherein the amplicon produced from each round of invasion / extension is used as a template in a subsequent round. Because denaturation cycles (such as by heating or chemical denaturation) are not required, this method can occur faster than standard PCR. Therefore, the amplification promoted by recombinases can be implemented isothermally. It is generally desirable to include ATP or other nucleotides (or in some cases, its non-hydrolyzable analogs) in the amplification reagents promoted by recombinases to promote amplification. A mixture of recombinase and single-stranded binding (SSB) protein is particularly useful because SSB can further promote amplification. Exemplary preparations for amplification promoted by recombinases include those sold commercially by TwistDx (Cambridge, UK) with TwistAmp test kits. Useful components and reaction conditions for recombinase-assisted amplification reagents are described in US Pat. Nos. 5,223,414 and 7,399,590, the contents of which are incorporated herein by reference.
[0133] Another example of a component that can be included in the amplification reagent to promote amplicon formation and increase the speed of amplicon formation in some cases is a helicase. Helicase can promote amplicon formation by a chain reaction that allows amplicon formation. Because denaturation cycles (e.g., by heating or chemical denaturation) are not required, the process can occur faster than standard PCR. Therefore, the amplification promoted by helicase can be implemented isothermally. The mixture of helicase and single-stranded binding (SSB) protein is particularly useful because SSB can further promote amplification. Exemplary formulations for the amplification promoted by helicase include those sold commercially from Biohelix (Beverly, MA) with IsoAmp test kits. In addition, examples of useful formulations including helicase proteins are described in US 7,399,590 and US 7,829,284, each of which is incorporated herein by reference.
[0134] Yet another example of a component that can be included in an amplification reagent to promote, and in some cases increase the rate of, amplicon formation is an origin binding protein.
[0135] Uses in sequencing / sequencing methods
[0136] The fixed polynucleotides from the pooled libraries can be sequenced in any suitable manner. Preferably, sequencing is performed by sequencing by synthesis, wherein nucleotides are continuously added to the free 3' hydroxyl group of the sequencing primer using the fixed polynucleotide as a template, resulting in the synthesis of the polynucleotide chain in the 5' to 3' direction. Preferably, the properties of the added nucleotides are determined after each nucleotide addition. Sequencing techniques using sequencing by ligation (wherein not every connected base is sequenced), and techniques such as massively parallel signature sequencing (MPSS) (wherein bases are removed from chains on the surface rather than added to chains on the surface), and techniques using pyrophosphate release detection (pyrophosphate sequencing) are also within the scope of the present disclosure. Such pyrophosphate sequencing-based techniques are particularly suitable for array sequencing of beads, where beads have been amplified in emulsions so that a single template from a library molecule is amplified on each bead.
[0137] A starting point for the sequencing reaction can be provided by annealing a sequencing primer to the product of a solid phase amplification reaction. In this regard, one or both adapters added during template library formation can include a nucleotide sequence that allows a sequencing primer to anneal to a fixed polynucleotide such as an adapter-target-adapter polynucleotide.
[0138] The index tag sequence and target sequence can be determined in a single read from a single sequencing primer, or in multiple reads from more than one sequencing primer. In the case of two reads from two sequencing primers, the "index tag read" and the "target read" can be performed in either order, with a suitable denaturation step after the first sequencing read is completed to remove the annealed primer. As is generally known in the art, suitable denaturation steps may include formamide treatment, hydroxide treatment, or heat treatment.
[0139] The product of a solid phase amplification reaction in which both a forward amplification primer and a reverse amplification primer are covalently fixed on a solid surface can be a so-called "bridged" structure formed by annealing of a fixed polynucleotide chain and a fixed complementary chain, both chains being attached to a solid support at the 5' end. An array comprising such a bridged structure cannot provide an effective template for nucleic acid sequencing because, under standard conditions for hybridization, hybridization of a conventional sequencing primer to one of the fixed chains is not supported compared to the fixed complementary chain to which the chain is annealed. Examples of bridge amplification or cluster amplification are described in, for example, U.S. Patents Nos. 7,985,565 and 7,115,400.
[0140] In order to provide a template that is more suitable for nucleic acid sequencing, it is preferred to substantially remove all of one of the fixed chains in the "bridged" structure, or remove or replace at least a portion of one of the fixed chains in the "bridged" structure, to produce a template that is at least partially single-stranded. The single-stranded portion of the template will therefore be used for hybridization with a sequencing primer. The process of removing all or a portion of a fixed chain in a "bridged" double-stranded nucleic acid structure can be referred to as "linearization" in this article, and is described in further detail in WO 2007 / 010251, WO 2006 / 064199, WO 2005 / 065814, WO 2015 / 106941, WO1998 / 044151 and WO 2000 / 018957.
[0141] The bridged template structure can be linearized by cleaving one or both strands with a restriction endonuclease or by cleaving one strand with a nicking endonuclease. Other methods of cleavage can be used as an alternative to restriction enzymes or nicking enzymes, including, inter alia, chemical cleavage (e.g., cleavage of diol linkages with periodate), cleavage by cleavage with an endonuclease (e.g., such as "USER" provided by NEB, part number M5505S) or by exposure to heat or alkali to cleave abasic sites (abasicsites), cleavage of ribonucleotides incorporated into amplification products that originally contained deoxyribonucleotides, photochemical cleavage, or cleavage of peptide linkers.
[0142] It will be appreciated that if the solid phase amplification reaction is performed with only one covalently immobilized primer and another primer in free solution, a linearization step may not be essential.
[0143] After the cleavage step, regardless of the method for cracking, the product of the cleavage reaction can undergo denaturation conditions to remove one or more parts of the chain of one or more cracks that are not attached to the solid support. Suitable denaturation conditions, such as sodium hydroxide solution, formamide solution or heating, for reference standard molecular biology protocols (Sambrook et al., 2001, Molecular Cloning, A Laboratory Manual, the 3rd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor Laboratory Press, NY; Current Protocols, Ausubel et al. write) skilled readers will be obvious. Denaturation causes the generation of partially or substantially single-stranded sequencing templates. Then the sequencing reaction can be initiated by hybridization of the single-stranded portion of the sequencing primer with the template.
[0144] Thus, in some embodiments, the sequencing reaction includes hybridizing a sequencing primer to a single-stranded region of a linearized amplification product, sequentially incorporating one or more nucleotides into a polynucleotide chain complementary to the region of the amplified template chain to be sequenced, identifying the bases present in the one or more incorporated nucleotides, and thereby determining the sequence of the region of the template chain.
[0145] A preferred sequencing method that can be used relies on the use of modified nucleotides with removable 3' closures, such as described in WO 2004 / 018497 and U.S. Patent No. 7,057,026. After the modified nucleotides have been incorporated into the growing polynucleotide chain complementary to the region of the template being sequenced, because there is no free 3'-OH group, it can be used to guide other sequence extensions, and therefore the polymerase cannot add other nucleotides. Once the nature of the bases incorporated into the growing chain is determined, the 3' closure can be removed to allow the next continuous nucleotide to be added. By sorting the products obtained using these modified nucleotides, it is possible to infer the DNA sequence of the DNA template. If the nucleotides of each modification have different markers attached thereto, it is known that the different markers correspond to specific bases to facilitate distinguishing between the bases added during each incorporation step, then such a reaction can be completed in a single experiment. Alternatively, the different reactions of the nucleotides comprising each modification can be implemented separately.
[0146] The modified nucleotide can carry a marker that helps it to detect. For example, a fluorescent marker can be used to detect the modified nucleotide. Each nucleotide type can therefore carry different fluorescent markers, for example as described in WO 2007 / 135368. However, detectable markers need not be fluorescent markers. Any marker that allows detection of the incorporated nucleotide can be used.
[0147] A method for detecting fluorescently labeled Nucleotide comprises using a laser with a wavelength specific to the Nucleotide of the mark, or uses other suitable illumination sources. Fluorescence from the marker on the Nucleotide can be detected by CCD camera or other suitable detection means. Suitable instruments for recording the image of cluster arrays are described in WO 2007 / 123744.
[0148] Of course, any other suitable sequencing method can be used. Preferably, the sequencing method relies on the continuous incorporation of nucleotides into the polynucleotide chain. Suitable alternative techniques include, for example, pyrophosphate sequencing, FISSEQ (fluorescence in situ sequencing), MPSS, and sequencing by a method based on connection, such as described in U.S. Patent No. 6,306,597.
[0149] The nucleic acid sample can be further analyzed to obtain a second read from the opposite end of the fragment. Methods for sequencing the two ends of the cluster are described in co-pending applications WO 2007 / 010252 and WO 2008 / 041002. In one example, a series of steps can be performed as follows: generate clusters, linearize, hybridize the first sequencing primer and obtain the first sequencing read. The first sequencing primer can be removed, the second primer is hybridized and the index tag is sequenced. The polynucleotide chain can then be "inverted" on the surface by synthesizing complementary copies from the remaining fixed primers used in cluster amplification. This process of chain resynthesis regenerates double-stranded clusters. The original template chain can be removed to linearize the resynthesized chain, which can then be annealed to the sequencing primer and sequenced in a third sequencing run.
[0150] Where strand resynthesis is used, the two strands may be fixed to the surface in a manner that allows for subsequent release of a portion of the fixed strand. This may be achieved by a number of mechanisms as described in WO 2007 / 010251. For example, a primer may comprise uracil nucleotides, which means that the strands may be cleaved at uracil bases using uracil glycosylase (UDG) to remove nucleoside bases and endonuclease VIII to excise abasic nucleotides. This enzyme combination is available from New England Biolabs (Cat# M5505) as USER TMEnzyme available. The second primer can contain 8-oxoguanine nucleotides, which can then be cleaved by the enzyme FPG (NEB Cat#M0240). This design of primers provides control over which primer is cleaved at which point in the process, and also at which positions in the cluster that cleavage occurs. Primers can also be chemically modified, such as with disulfide or diol modifications that allow chemical cleavage at specific positions.
[0151] Reference now Figure 1 , a schematic diagram of an adaptor 100 that can be used according to multiple embodiments described herein is shown. The depicted adaptor 100 comprises a double-stranded region 110 and a non-complementary single-stranded region 120. The double-stranded region 110 can be attached to a double-stranded target polynucleotide. In the depicted embodiment, the free ends of each chain of the single-stranded portion 120 are modified (indicated by "X") to protect these ends from exonuclease activity. In contrast, the 3' end of one chain forming the double-stranded portion 110 and the 5' end of the other chain are susceptible to exonuclease degradation. If the adaptor 100 is not attached to the double-stranded target fragment, the unincorporated adaptor can be degraded by one or more exonucleases having both 5' exonuclease activity and 3' exonuclease activity. Because the exonuclease will start digestion from the double-stranded portion 110, the exonuclease preferably has activity against double-stranded DNA without a nick.
[0152] One strand of the depicted adaptor 100 comprises a universal extension primer sequence 130, an index tag sequence 132, and a sequencing primer sequence 134. The other strand of the depicted adaptor 100 comprises a universal extension primer sequence 140, an index tag sequence 142, and a sequencing primer sequence 144.
[0153] Universal extension primer sequences 130, 140 can hybridize with extension primer oligonucleotides attached to a solid surface for amplification or sequencing purposes (if adaptor 100 is attached to a target polynucleotide). Universal extension primer sequence 140 or a portion thereof can also hybridize with a sequencing primer to sequence index tag sequence 142. Optionally, the strand can include additional sequencing primer sequences (not shown).
[0154] Sequencing primer sequence 134 may hybridize to a sequencing primer to allow sequencing of index tag sequence 132. Index tag sequence 142 and index tag sequence 132 may be the same or different.
[0155] Sequencing primer sequence 144 can hybridize to a sequencing primer to allow sequencing of the target polynucleotide sequence (if attached to adaptor 100).
[0156] If the adaptors are attached to the target in a multi-step process as described above, the sequencing primer sequences 134, 144 can hybridize to, for example, PCR primers.
[0157] It will be appreciated that suitable adaptors for use in the various embodiments described herein may have more Figure 1 The described sequence features may have more or fewer sequence features or other sequence features in addition to those sequence features.
[0158] Reference now Figure 2 , a schematic diagram of a template polynucleotide 200 of a library having an adapter 100-template fragment 210-adapter 100 sequence is shown. The template fragment 210 is double-stranded and attached to the double-stranded portion of the adapter 100. The ends of the single-stranded portion of the adapter are modified to protect against exonuclease digestion (indicated by "X"). Because the adapter 100 is attached to both ends of the double-stranded target fragment 210, the resulting template polynucleotide 200 is resistant to exonuclease digestion.
[0159] Reference now Figure 3 , shows a schematic diagram illustrating the result of incubating the reaction products and reagents of the adapter-target ligation with the exonuclease 400. After the adapter 100 is ligated to the target fragment 210, some remaining unincorporated adapter 100, target fragment 210, and template polynucleotide 200 are obtained. If the resulting solution or composition 500 is incubated with an exonuclease 400 having 5' exonuclease activity and an exonuclease 400 having 3' exonuclease activity, the unincorporated adapter 100 and target fragment 210 will be digested by the exonuclease 400 (see Figure 3 ). After exonuclease treatment, the resulting solution can be cleaned up and the template polynucleotide 200 can be immobilized on a solid surface for sequencing.
[0160] Reference now Figure 4 , shows a schematic illustration of the process for amplifying a template polynucleotide 200 from a library cluster to a solid surface 300 in preparation for sequencing. In the first figure, a template polynucleotide 200 with a modified end (for nuclease protection) is hybridized to a first extension primer 310 attached to a solid surface 300. For example, Figure 1 The adapter portion of the universal extension primer sequence 140 depicted in can hybridize to the first extension primer 310.
[0161] The first extension primer 310 contains a free 3' end, and thus a nucleotide can be added to the 3' end in the presence of a suitable polymerase using the template polynucleotide 200 as a template to produce a copy template strand 201 attached to the solid surface 300 (see the second figure). The template polynucleotide 200 can be removed, and the copy template strand 201 can be hybridized with the second extension primer 320 attached to the solid surface 300 (see the third figure). For example, Figure 1The universal extension primer sequence 130 portion of the adapter depicted in can hybridize to the second extension primer 320.
[0162] The second extension primer 320 contains a free 3' end, and thus a nucleotide can be added to the 3' end in the presence of a suitable polymerase using the copy template strand 201 as a template to produce an amplified template strand 202 (see fourth figure) attached to the solid surface 300. Additional rounds of amplification can be performed to produce clusters of the copy template strand 201 and the amplified template strand 202.
[0163] For illustration purposes, Figure 4 The fifth figure of FIG. 1 depicts the copied template strand 201 and the amplified template strand 202 in linear form.
[0164] Reference now Figure 5 , shows a schematic diagram illustrating how exonuclease treatment to remove unincorporated adaptors can reduce index jumping. Figure 5 The first two pictures and Figure 4 The first two pictures are the same. Figure 5 As shown in the lower left figure of , the remaining unincorporated (not attached to the target polynucleotide) adapter or its chain 104 can hybridize with the adapter portion of the copy template chain 201 (for example, hybridization can occur between the double-stranded region of the adapter and the adapter portion of the template polynucleotide). The adapter chain 104 can come from a library different from the library from which the copy template chain 201 originated. Therefore, the adapter chain 104 can have an index tag sequence that is different from the index tag sequence associated with the copy template chain 201. The adapter chain 104 can be used as an effective primer for extending and copying the copy template chain 201. An amplified chain will be produced in which the incorrect index tag (the index tag of the adapter chain 104 from the second library) will be associated with a target polynucleotide from another library (the target polynucleotide of the copy template chain 201 from the first library). In a subsequent round of amplification, the incorrectly indexed polynucleotide can be attached to the surface 300. However, and as Figure 5 As illustrated in the lower right figure of , if unincorporated adapters are digested by exonuclease treatment, the adapter strands cannot serve as extension primers and index hopping is reduced.
[0165] Reference now Fig. 6A and 6B , illustrating the nature of the index jumping phenomenon. Fig. 6A It shows how reads from a given sample can be incorrectly demultiplexed and mixed with different samples after demultiplexing. Figure 6B We demonstrate index hopping in a dual-index system, where it leads to unexpected combinations of index label sequences.
[0166] Reference now Fig. 7A and7B , illustrates a general method for measuring the index jump rate in a given system. Fig. 7A An exemplary layout of a dual adaptor plate is shown, where each individual well of a 96-well plate contains a unique pair of index tag sequences (12 different P7 indices combined with 8 different P5 indices). Figure 7B An experimental setup designed to measure index jump rates is shown, where 8 unique dual-index tag combinations are used (i.e. no P5 index is expected to be paired with more than one P7 index, and vice versa). Unexpected combinations of index tags (e.g. D505-D703) are then easily identified as cases of index jumps.
[0167] Reference now Fig. 8A and 8B , illustrating the effect of unligated adapters on index hopping rate. Fig. 8A A 6-fold increase in the index jump associated with 50% incorporation of free adaptor is shown. Figure 8B A roughly linear effect of free forked adaptors on index jump rate is shown over the range tested. The inventors also observed that free single-stranded P7 adaptors had a more pronounced effect on index jump rate than free single-stranded P5 adaptors (data not shown). Example
[0168] Example 1: Demonstration of exonuclease treatment and 3' blocking of an indexed library of protected adaptors Example
[0169] This protocol explains how to perform exonuclease treatment and 3' blocking of protected DNA libraries to reduce index hopping. The method is designed to be performed on a pool of DNA libraries and then analyzed using Illumina 4000 and similar sequencing platforms (using patterned flow cells and ExAmp-based clustering) (e.g., X and ) for the denaturation step and subsequent cluster generation.
[0170] Index jumping has been observed to occur when incorrect index sequences are assigned to insert sequences, resulting in sample misassignment. Such treatment of the DNA sample pool prior to running on the 4000 should reduce the level of index jumping to a level that cannot be consistently predicted at this stage.
[0171] The processing workflow can be considered to include four steps: (i) generating DNA sample pools; (ii) performing processing, (iii) cleaning up samples and quantifying; and (iv) clustering and sequencing the sample pools.
[0172] Consumables / Equipment: Consumables and equipment can be provided by the sequencing user or manufacturer. User-supplied consumables can include a DNA library sample pool—30 μl at a concentration to be used for denaturation during clustering. The user can also provide freshly prepared 80% ethanol (EtOH).
[0173] Table 1 below describes some of the consumables and equipment that may be used.
[0174] Table 1: Consumables and Equipment
[0175]
[0176] Sequencing manufacturers may provide EMX (exonuclease mix), BMX (blocking mix), RSB (resuspension buffer), and SPB (sample purification beads).
[0177] EMX can include exonuclease buffer (NEBuffer 4, NEB Cat#B7004S: 50 mM potassium acetate, 20 mM Tris-acetate, 10 mM magnesium acetate, 1 mM DTT) and Exonuclease V (New England Biolabs, Cat#M0345S / L).
[0178] BMX can include sequencing premix (Tris buffer, sodium chloride, sucrose, magnesium sulfate, EDTA and Tween20), ddNTP mixture, Pol19 DNA polymerase and TdT terminal transferase.
[0179] RSB may include Tris buffer, pH 8.5.
[0180] SPBs can include XP beads (Beckman Coulter, Cat# A63880). SPB should be vortexed before each use. SPB should be vortexed frequently to ensure even distribution of beads. Due to the viscosity of the solution, the SPB should be aspirated and dispersed slowly.
[0181] Some consumables should be stored and prepared as indicated in Table 2 below.
[0182] Table 2: Storage and preparation of consumables
[0183]
[0184]
[0185] The following EMX program can be saved on the thermal cycler: (i) select preheat lid option and set to 100°C; (ii) 37°C for 5 min; (iii) 70°C for 30 min; and (iv) hold at 4°C.
[0186] The following BMX program can be saved on the thermal cycler: (i) select preheat lid option and set to 100°C; (ii) 38°C for 20 min; (iii) 60°C for 20 min; and (iv) hold at 4°C.
[0187] Samples can be processed as follows: (i) EMX is centrifuged at 600×g for 5 seconds; (ii) 27 μl of the DNA library sample pool is added to the PCR tube; (iii) 5 μl of EMX is added to each sample in each PCR tube and then mixed thoroughly by pipetting up and down; (iv) incubated by placing on a thermal cycler and running the EMX program; (v) BMX is centrifuged at 600×g for 5 seconds; (vi) 32 μl of BMX is added directly to each exonuclease reaction in each PCR tube and then mixed thoroughly by pipetting up and down; and (vii) incubated by placing on a thermal cycler and running the BMX program. Each tube contains 64 μl.
[0188] The processed pooled samples can be cleaned up as follows: (1) vortex SPB until well dispersed; (2) add 60 μl SPB to each sample processing tube and mix thoroughly by pipetting up and down; (3) incubate at room temperature for 5 minutes; (4) place on a magnetic stand and wait for the liquid to clarify (2 minutes to 5 minutes); (5) remove and discard all supernatant from each tube; (6) wash twice as follows: (a) add 200 μl of freshly prepared 80% EtOH to each tube, (b) incubate on a magnetic stand for 30 seconds, and (c) remove and discard all supernatant from each tube; (7) remove remaining EtOH from each tube using a 20 μl pipette; (8) air dry on a magnetic stand for 5 minutes; (9) add 22.5 μl Add RSB to each tube; (10) Remove from magnetic stand and then mix thoroughly by pipetting up and down; (11) Incubate at room temperature for 2 minutes; (12) Place on magnetic stand and wait for liquid to clear (2 minutes-5 minutes); (13) Transfer 20 μl of supernatant to a new tube; (14) If necessary, quantify the library and perform standard clustering for use starting with the NaOH denaturation step. 4000 platform; and (15) if not clustered immediately, stored at -25°C to -15°C.
[0189] Example 2: Exonuclease treatment of indexed libraries with protected adapters and 3' Closure reduces index jumping
[0190] The processing protocol described in Example 1 above can be applied in combination with the following materials, equipment, and methods to facilitate clustering and sequencing on the Illumina platform.
[0191] Experimental conditions:(1) Human 450 bp NA12878 (Coriell Institute) prepared using phosphorothioate protected adapters No PCR library, loaded at 300 pM; (2) according to the manufacturer's instructions X instrument and Illumina SBS chemistry; (3) 550 nm ILS v3 flow cell; (4) ExAmp amplification as previously described; and (5) 50% adapter incorporation: free forked adapters from an Illumina dual adapter plate (DAP) were incorporating into the template library followed by denaturation, neutralization, addition of ExAmp mix, and clustering.
[0192] The results of this experiment are summarized in Tables 3 and Fig. 9 middle.
[0193] Table 3: Exonuclease treatment of protected adapters with 3' blocking reduces index jumping
[0194]
[0195] As explained above, the combination of exonuclease treatment of protected adaptors and 3' blocking reduces index jumping.
[0196] Any patent, patent application (whether published or not), or other document cited herein is hereby incorporated herein in whole or in part, to the extent it is not inconsistent with the disclosure presented herein.
[0197] In addition to the documents already cited in this application, reference is made here to three provisional patent applications with the same name of "Compositions and methods for improving sample identification in indexed nucleic acid libraries", which are filed on the same day as the provisional applications (U.S. provisional applications No. 62 / 488,824, No. 62 / 488,825 and No. 62 / 488,833 filed on April 23, 2018) to which this application claims priority. The entire contents of these applications are also incorporated herein by reference.
[0198] It will be apparent to those skilled in the art that various modifications and variations may be made to the technology of the present invention without departing from the spirit and scope of the present invention. Because those skilled in the art may conceive of modifications, combinations, sub-combinations and variations of the disclosed embodiments that embody the spirit and essence of the technology of the present invention, the technology of the present invention should be understood to include all solutions within the scope of the appended claims and their equivalents.
[0199] This article also provides the following items:
[0200] 1. A method, comprising:
[0201] providing a first plurality of double-stranded target polynucleotide fragments, each fragment having a first end and a second end;
[0202] providing a first adaptor oligonucleotide comprising a first strand having a 5' end and a 3' end and a second strand having a 5' end and a 3' end,
[0203] wherein the first adaptor oligonucleotide comprises (i) a double-stranded region comprising the 5' end of the first strand and the 3' end of the second strand, and (ii) a single-stranded region in which the first strand and the second strand are single-stranded, wherein the single-stranded region comprises the 3' end of the first strand and the 5' end of the second strand,
[0204] wherein the first adaptor oligonucleotide comprises a first library-specific sequence,
[0205] wherein the 3' end of the first strand is modified to prevent digestion by an enzyme having 3' exonuclease activity, and wherein the 5' end of the second strand is modified to prevent digestion by an enzyme having 5' exonuclease activity;
[0206] incubating the first adaptor oligonucleotide and the first more than one double-stranded target polynucleotide fragments under conditions suitable for ligating the 5' end of the first strand of the first adaptor and the 3' end of the second strand of the first adaptor to the first end and the second end of the double-stranded target polynucleotide fragments to generate a first library of polynucleotides comprising first adaptor-target-first adaptor sequences; and
[0207] The polynucleotides of the first library are contacted with an exonuclease, wherein the exonuclease comprises a 3' single-stranded exonuclease activity and a 5' single-stranded exonuclease activity to selectively degrade the first adaptor oligonucleotide that is not ligated to the double-stranded target polynucleotide fragment.
[0208] 2. The method according to item 1, wherein the exonuclease includes activity against double-stranded DNA without a nick to degrade double-stranded target polynucleotide fragments whose two ends are not connected to the first adaptor oligonucleotide.
[0209] 3. The method according to item 1 or item 2,
[0210] wherein the 3' end of the first strand of the first adaptor comprises a phosphorothioate bond, wherein a single-stranded DNA binding protein binds to the 3' end of the first strand of the first adaptor, wherein biotin is attached to the 3' end of the first strand of the first adaptor, or wherein an antibody is attached to the 3' end of the first strand of the first adaptor; and
[0211] wherein the 5' end of the second strand of the first adaptor comprises a phosphorothioate bond, wherein a single-stranded DNA binding protein binds to the 5' end of the second strand of the first adaptor, wherein biotin is attached to the 5' end of the second strand of the first adaptor, or wherein an antibody is attached to the 5' end of the second strand of the adaptor.
[0212] 4. A method according to item 1 or item 2, wherein the 3' end of the first chain of the first adaptor comprises three phosphorothioate bonds, and wherein the 5' end of the second chain of the first adaptor comprises three phosphorothioate bonds.
[0213] 5. A method according to any one of items 1 to 4, wherein the polynucleotides of the first library are purified.
[0214] 6. The method according to any one of items 1 to 5, further comprising:
[0215] providing a substrate having a surface comprising more than one attached oligonucleotide having a free 3' end; and
[0216] The surface of the substrate is contacted with a composition comprising purified polynucleotides of the first library under conditions that allow a portion of one strand of the first adaptor of the first adaptor-target-first adaptor sequence to hybridize to at least a portion of the oligonucleotides attached to the surface of the substrate.
[0217] 7. The method according to item 6 further comprises extending the attached oligonucleotide from the free 3' end by incorporating nucleotides complementary to the sequence of the first linker-target-first linker polynucleotide that hybridizes to the oligonucleotide attached to the surface of the substrate to produce a copy of the hybridized first library polynucleotide so that the copy is attached to the surface of the substrate.
[0218] 8. The method according to item 7 further comprises amplifying the copies attached to the surface of the substrate.
[0219] 9. The method according to any one of items 1 to 8, wherein the method further comprises:
[0220] providing a second one or more double-stranded target polynucleotide fragments, each fragment having a first end and a second end;
[0221] providing a second adaptor oligonucleotide comprising a first strand having a 5' end and a 3' end and a second strand having a 5' end and a 3' end,
[0222] wherein the second adaptor oligonucleotide comprises (i) a double-stranded region comprising the 5' end of the first strand and the 3' end of the second strand, and (ii) a single-stranded region comprising the 3' end of the first strand and the 5' end of the second strand,
[0223] wherein the 3' end of the first strand is modified to prevent digestion by an enzyme having 3' exonuclease activity, and wherein the 5' end of the second strand is modified to prevent digestion by an enzyme having 5' exonuclease activity;
[0224] wherein the second adaptor comprises a second library-specific sequence different from the first library-specific sequence;
[0225] incubating the second adaptor oligonucleotide and the second more than one double-stranded target polynucleotide fragments under conditions suitable for ligating the 5' end of the first strand of the second adaptor and the 3' end of the second strand of the second adaptor to the first and second ends of the double-stranded target polynucleotide fragments to produce a second library of polynucleotides comprising second adaptor-target-second adaptor sequences; and
[0226] The polynucleotides of the second library are contacted with an exonuclease, wherein the exonuclease comprises a 3' single-stranded exonuclease activity and a 5' single-stranded exonuclease activity to selectively degrade the second adaptor oligonucleotides that are not ligated to the double-stranded target polynucleotide fragments.
[0227] 10. The method according to item 9, wherein the exonuclease contacted with the polynucleotide of the second library includes activity against double-stranded DNA without nicks to degrade the double-stranded target polynucleotide fragments whose two ends are not connected to the second adaptor oligonucleotide.
[0228] 11. The method according to item 9 or item 10,
[0229] wherein the 3' end of the first strand of the second adaptor comprises a phosphorothioate bond, wherein a single-stranded DNA binding protein binds to the 3' end of the first strand of the second adaptor, wherein biotin is attached to the 3' end of the first strand of the second adaptor, or wherein an antibody binds to the 3' end of the first strand of the second adaptor; and
[0230] wherein the 5' end of the second chain of the second adaptor comprises a phosphorothioate bond, wherein a single-stranded DNA binding protein binds to the 5' end of the second chain of the second adaptor, or wherein biotin is attached to the 5' end of the second chain of the second adaptor, or wherein an antibody binds to the 5' end of the second chain of the second adaptor.
[0231] 12. A method according to item 9 or item 10, wherein the 3' end of the first chain of the second adaptor comprises three phosphorothioate bonds, and wherein the 5' end of the second chain of the second adaptor comprises three phosphorothioate bonds.
[0232] 13. The method according to any one of items 9 to 12, wherein the polynucleotides of the second library are purified.
[0233] 14. The method according to item 13, wherein purifying the polynucleotides of the second library and purifying the polynucleotides of the first library include combining the polynucleotides of the second library and the polynucleotides of the first library and purifying the polynucleotides of the first library and the second library at the same time.
[0234] 15. The method according to item 13, further comprising:
[0235] providing a substrate having a surface comprising more than one attached oligonucleotide having a free 3' end; and
[0236] The surface of the substrate is contacted with a composition comprising purified polynucleotides of the second library under conditions that allow a portion of one strand of the second adaptor of the second adaptor-target-second adaptor sequence to hybridize to at least a portion of the oligonucleotides attached to the surface of the substrate.
[0237] 16. The method according to item 15 further comprises extending the attached oligonucleotide from the free 3' end by incorporating nucleotides complementary to the sequence of the second linker-target-second linker polynucleotide that hybridizes to the oligonucleotide attached to the surface of the substrate to produce a copy of the hybridized second library polynucleotide so that the copy is attached to the surface of the substrate.
[0238] 17. The method according to item 16 further comprises amplifying copies of the second library polynucleotides attached to the surface of the substrate.
[0239] 18. An oligonucleotide adaptor for ligating to a target polynucleotide prior to sequencing, the oligonucleotide adaptor comprising:
[0240] a first oligonucleotide strand having a 5' end and a 3' end; and
[0241] a second oligonucleotide strand having a 5' end and a 3' end,
[0242] wherein the region at the 5' end of the first strand comprises nucleotides that are complementary to nucleotides in the region at the 3' end of the second strand, such that the complementary region is double-stranded,
[0243] wherein the region at the 3' end of the first strand and the region at the 5' end of the second strand are sufficiently non-complementary to be single-stranded,
[0244] wherein at least one of the first strand and the second strand comprises a library-specific index tag sequence, and
[0245] wherein the 3' end of the first strand is modified to prevent digestion by an enzyme having 3' exonuclease activity, and wherein the 5' end of the second strand is modified to prevent digestion by an enzyme having 5' exonuclease activity.
[0246] 19. The oligonucleotide adaptor according to item 18,
[0247] wherein the double-stranded region is double-stranded under standard ligation conditions, and
[0248] The single-stranded region is single-stranded under standard ligation conditions.
[0249] 20. The oligonucleotide adaptor according to item 18 or item 19,
[0250] wherein the 3' end of the first strand comprises a phosphorothioate bond, wherein a single-stranded DNA binding protein binds to the 3' end of the first strand, wherein biotin is attached to the 3' end of the first strand, or wherein an antibody is attached to the 3' end of the first strand; and
[0251] wherein the 5' end of the second strand comprises a phosphorothioate bond, wherein a single-stranded DNA binding protein binds to the 5' end of the second strand, wherein biotin is attached to the 5' end of the second strand, or wherein an antibody is attached to the 5' end of the second strand.
[0252] 21. A method according to item 18 or item 19, wherein the 3' end of the first strand comprises three phosphorothioate bonds, and wherein the 5' end of the second strand comprises three phosphorothioate bonds.
[0253] 22. A kit, comprising:
[0254] An oligonucleotide adaptor according to any one of items 18-21; and an exonuclease.
[0255] 23. The kit according to item 22, wherein the exonuclease comprises 3' exonuclease activity and 5' exonuclease activity.
[0256] 24. The kit according to item 22 or item 23, wherein the exonuclease comprises activity against unnicked double-stranded DNA.
[0257] 25. The kit according to item 22, wherein the exonuclease comprises a first exonuclease having 3' exonuclease activity and a second exonuclease having 5' exonuclease activity.
[0258] 26. The kit according to item 22, wherein the exonuclease is Exonuclease V.
[0259] 27. A composition comprising the adaptor according to any one of items 18-21; and an exonuclease.
[0260] 28. A composition comprising:
[0261] An adaptor according to any one of items 18-21; and
[0262] More than one double-stranded target polynucleotide fragment, each fragment having a first end and a second end.
[0263] 29. The composition according to item 28, further comprising a ligase.
[0264] 30. A composition comprising:
[0265] more than one polynucleotide, the more than one polynucleotide comprising a first adaptor-target-second adaptor sequence,
[0266] wherein the target sequence is double-stranded, the first adaptor is double-stranded in a region near the target, the second adaptor is double-stranded in a region near the target, the first adaptor comprises two single strands each having one end in a region distal to the target, and the second adaptor comprises two single strands each having one end in a region distal to the target,
[0267] wherein at least one of the two single strands of the first adaptor or the second adaptor comprises a library-specific index tag sequence, and
[0268] Each end of the two single strands of the first adaptor and the second adaptor is modified to prevent digestion by exonucleases.
[0269] 31. The composition according to item 30, wherein each of the two single strands of the first adaptor and the second adaptor comprises a phosphorothioate bond.
[0270] 32. A composition according to item 30, wherein each of the two single strands of the first adaptor and the second adaptor comprises three phosphorothioate bonds.
[0271] 33. The composition according to any one of items 30-32, further comprising:
[0272] an adaptor comprising a first oligonucleotide strand having a 5' end and a 3' end and a second oligonucleotide strand having a 5' end and a 3' end,
[0273] wherein the region at the 5' end of the first strand comprises nucleotides that are complementary to nucleotides in the region at the 3' end of the second strand, such that the complementary region is double-stranded,
[0274] wherein the region at the 3' end of the first strand and the region at the 5' end of the second strand are sufficiently non-complementary to be single-stranded,
[0275] wherein at least one of the first strand and the second strand comprises a library-specific index tag sequence, and
[0276] wherein the 3' end of the first strand is modified to prevent digestion by an enzyme having 3' exonuclease activity, and wherein the 5' end of the second strand is modified to prevent digestion by an enzyme having 5' exonuclease activity.
[0277] 34. The composition according to any one of items 30-33, further comprising an exonuclease.
Claims
1. A method, the method include: providing a first plurality of double-stranded target polynucleotide fragments, each fragment having a first end and a second end; providing a first adaptor oligonucleotide comprising a first strand having a 5' end and a 3' end and a second strand having a 5' end and a 3' end, wherein the first adaptor oligonucleotide comprises (i) a double-stranded region comprising the 5' end of the first strand and the 3' end of the second strand, and (ii) a single-stranded region in which the first strand and the second strand are single-stranded, wherein the single-stranded region comprises the 3' end of the first strand and the 5' end of the second strand, wherein the first adaptor oligonucleotide comprises a first library-specific sequence, wherein the 3' end of the first strand is modified to prevent digestion by an enzyme having 3' exonuclease activity, and wherein the 5' end of the second strand is modified to prevent digestion by an enzyme having 5' exonuclease activity; incubating the first adaptor oligonucleotide and the first more than one double-stranded target polynucleotide fragments under conditions suitable for ligating the 5' end of the first strand of the first adaptor oligonucleotide and the 3' end of the second strand of the first adaptor oligonucleotide to the first end and the second end of the double-stranded target polynucleotide fragments to generate a first library of polynucleotides comprising first adaptor-target-first adaptor sequences; and The polynucleotides of the first library are contacted with an exonuclease, wherein the exonuclease comprises a 3' single-stranded exonuclease activity and a 5' single-stranded exonuclease activity to selectively degrade the first adaptor oligonucleotide that is not ligated to the double-stranded target polynucleotide fragment. 2 . The method according to claim 1 , wherein the exonuclease comprises an activity against unnicked double-stranded DNA to degrade double-stranded target polynucleotide fragments whose two ends are not connected to the first adaptor oligonucleotide.
3. The method according to claim 1 or claim 2, wherein the 3' end of the first strand of the first adaptor oligonucleotide comprises a phosphorothioate bond, wherein a single-stranded DNA binding protein binds to the 3' end of the first strand of the first adaptor oligonucleotide, wherein biotin is attached to the 3' end of the first strand of the first adaptor oligonucleotide, or wherein an antibody is attached to the 3' end of the first strand of the first adaptor oligonucleotide; and wherein the 5' end of the second strand of the first adaptor oligonucleotide comprises a phosphorothioate bond, wherein a single-stranded DNA binding protein binds to the 5' end of the second strand of the first adaptor oligonucleotide, wherein biotin is attached to the 5' end of the second strand of the first adaptor oligonucleotide, or wherein an antibody is attached to the 5' end of the second strand of the first adaptor oligonucleotide.
4. The method of claim 1 or claim 2, wherein the 3' end of the first strand of the first adaptor oligonucleotide comprises three phosphorothioate bonds, and wherein the 5' end of the second strand of the first adaptor oligonucleotide comprises three phosphorothioate bonds.
5. The method according to any one of claims 1 to 4, wherein the polynucleotides of the first library are purified.
6. The method according to any one of claims 1 to 5, further comprising: include: providing a substrate having a surface comprising more than one attached oligonucleotide having a free 3' end; and The surface of the substrate is contacted with a composition comprising polynucleotides of a first library under conditions that allow a portion of one strand of the first adaptor of the first adaptor-target-first adaptor sequence to hybridize to at least a portion of the attached oligonucleotides attached to the surface of the substrate.
7. The method according to claim 6 further comprises extending the attached oligonucleotide from the free 3' end by incorporating nucleotides complementary to the sequence of the first adaptor-target-first adaptor polynucleotide that hybridizes to the oligonucleotide attached to the surface of the substrate to produce a copy of the hybridized first library polynucleotide so that the copy is attached to the surface of the substrate.
8. The method of claim 7, further comprising amplifying the copies attached to the surface of the substrate.
9. The method according to any one of claims 1 to 8, wherein the method further comprises include: providing a second one or more double-stranded target polynucleotide fragments, each fragment having a first end and a second end; providing a second adaptor oligonucleotide comprising a first strand having a 5' end and a 3' end and a second strand having a 5' end and a 3' end, wherein the second adaptor oligonucleotide comprises (i) a double-stranded region comprising the 5' end of the first strand of the second adaptor oligonucleotide and the 3' end of the second strand of the second adaptor oligonucleotide, and (ii) a single-stranded region comprising the 3' end of the first strand of the second adaptor oligonucleotide and the 5' end of the second strand of the second adaptor oligonucleotide, wherein the 3' end of the first strand of the second adaptor oligonucleotide is modified to prevent digestion by an enzyme having 3' exonuclease activity, and wherein the 5' end of the second strand of the second adaptor oligonucleotide is modified to prevent digestion by an enzyme having 5' exonuclease activity; wherein the second adaptor oligonucleotide comprises a second library-specific sequence that is different from the first library-specific sequence; incubating the second adaptor oligonucleotide and the second more than one double-stranded target polynucleotide fragments under conditions suitable for ligating the 5' end of the first strand of the second adaptor oligonucleotide and the 3' end of the second strand of the second adaptor oligonucleotide to the first end and the second end of the double-stranded target polynucleotide fragments to produce a second library of polynucleotides comprising second adaptor-target-second adaptor sequences; and The polynucleotides of the second library are contacted with an exonuclease, wherein the exonuclease comprises a 3' single-stranded exonuclease activity and a 5' single-stranded exonuclease activity to selectively degrade the second adaptor oligonucleotides that are not ligated to the double-stranded target polynucleotide fragments.
10. The method according to claim 9, wherein the exonuclease contacted with the polynucleotides of the second library comprises an activity against double-stranded DNA without a nick, so as to degrade the double-stranded target polynucleotide fragments whose two ends are not connected to the second adaptor oligonucleotide.
11. The method according to claim 9 or claim 10, wherein the 3' end of the first strand of the second adaptor oligonucleotide comprises a phosphorothioate bond, wherein a single-stranded DNA binding protein binds to the 3' end of the first strand of the second adaptor oligonucleotide, wherein biotin is attached to the 3' end of the first strand of the second adaptor oligonucleotide, or wherein an antibody binds to the 3' end of the first strand of the second adaptor oligonucleotide; and wherein the 5' end of the second strand of the second adaptor oligonucleotide comprises a phosphorothioate bond, wherein a single-stranded DNA binding protein binds to the 5' end of the second strand of the second adaptor oligonucleotide, or wherein biotin is attached to the 5' end of the second strand of the second adaptor oligonucleotide, or wherein an antibody binds to the 5' end of the second strand of the second adaptor oligonucleotide.
12. The method of claim 9 or claim 10, wherein the 3' end of the first strand of the second adaptor oligonucleotide comprises three phosphorothioate bonds, and wherein the 5' end of the second strand of the second adaptor oligonucleotide comprises three phosphorothioate bonds.
13. The method according to any one of claims 9 to 12, wherein the polynucleotides of the second library are purified.
14. The method of claim 13, wherein purifying the polynucleotides of the second library and purifying the polynucleotides of the first library comprise combining the polynucleotides of the second library and the polynucleotides of the first library and purifying the polynucleotides of the first library and the second library simultaneously.
15. The method according to claim 13, further comprising: include: providing a substrate having a surface comprising more than one attached oligonucleotide having a free 3' end; and The surface of the substrate is contacted with a composition comprising purified polynucleotides of the second library under conditions that allow a portion of one strand of the second adaptor of the second adaptor-target-second adaptor sequence to hybridize to at least a portion of the oligonucleotides attached to the surface of the substrate.
16. The method of claim 15, further comprising extending the attached oligonucleotide from the free 3' end by incorporating nucleotides complementary to the sequence of the second adaptor-target-second adaptor polynucleotide that hybridizes to the oligonucleotide attached to the surface of the substrate to produce a copy of the hybridized second library polynucleotide such that the copy is attached to the surface of the substrate.
17. The method of claim 16, further comprising amplifying copies of the second library polynucleotides attached to the surface of the substrate.
18. Use of an oligonucleotide adaptor and an exonuclease in the preparation of a kit, wherein the kit is used in the method according to any one of claims 1 to 17, and wherein the oligonucleotide adaptor include: a first strand having a 5' end and a 3' end; and a second strand having a 5' end and a 3' end, wherein the region at the 5' end of the first strand comprises nucleotides that are complementary to nucleotides in the region at the 3' end of the second strand, such that the complementary region is double-stranded, wherein the region at the 3' end of the first strand and the region at the 5' end of the second strand are sufficiently non-complementary to be single-stranded, wherein at least one of the first strand and the second strand comprises a library-specific index tag sequence, and wherein the 3' end of the first strand is modified to prevent digestion by an enzyme having 3' exonuclease activity, and wherein the 5' end of the second strand is modified to prevent digestion by an enzyme having 5' exonuclease activity.
19. The use according to claim 18, wherein the double-stranded region is double-stranded under standard ligation conditions, and The single-stranded region is single-stranded under standard ligation conditions.
20. The use according to claim 18 or claim 19, wherein the 3' end of the first strand comprises a phosphorothioate bond, wherein a single-stranded DNA binding protein binds to the 3' end of the first strand, wherein biotin is attached to the 3' end of the first strand, or wherein an antibody is attached to the 3' end of the first strand; and wherein the 5' end of the second strand comprises a phosphorothioate bond, wherein a single-stranded DNA binding protein binds to the 5' end of the second strand, wherein biotin is attached to the 5' end of the second strand, or wherein an antibody is attached to the 5' end of the second strand.
21. The use of claim 18 or claim 19, wherein the 3' end of the first strand comprises three phosphorothioate bonds, and wherein the 5' end of the second strand comprises three phosphorothioate bonds.
